A Collection of Target Mimics for Comprehensive Analysis of MicroRNA Function in Arabidopsis thalian
- 格式:pdf
- 大小:3.10 MB
- 文档页数:10
高三现代科技前沿探索英语阅读理解20题1<背景文章>Artificial intelligence (AI) is rapidly transforming the field of healthcare. In recent years, AI has made significant progress in various aspects of medical care, bringing new opportunities and challenges.One of the major applications of AI in healthcare is in disease diagnosis. AI-powered systems can analyze large amounts of medical data, such as medical images and patient records, to detect diseases at an early stage. For example, deep learning algorithms can accurately identify tumors in medical images, helping doctors make more accurate diagnoses.Another area where AI is making a big impact is in drug discovery. By analyzing vast amounts of biological data, AI can help researchers identify potential drug targets and design new drugs more efficiently. This can significantly shorten the time and cost of drug development.AI also has the potential to improve patient care by providing personalized treatment plans. Based on a patient's genetic information, medical history, and other factors, AI can recommend the most appropriate treatment options.However, the application of AI in healthcare also faces some challenges. One of the main concerns is data privacy and security. Medicaldata is highly sensitive, and ensuring its protection is crucial. Another challenge is the lack of transparency in AI algorithms. Doctors and patients need to understand how AI makes decisions in order to trust its recommendations.In conclusion, while AI holds great promise for improving healthcare, it also poses significant challenges that need to be addressed.1. What is one of the major applications of AI in healthcare?A. Disease prevention.B. Disease diagnosis.C. Health maintenance.D. Medical education.答案:B。
Genome editing in iPSCsCrispr designWe used the Feng Zhang lab CRISPR Design tool () to design the guide RNA. The guide RNA should bind as closely as possible to the target nucleotide (ideally between 2-10 bp).To correct a mutation, the mutated DNA sequence should be used for the gRNA design.To introduce a mutation, the wild-type DNA sequence should be used for the gRNA design.For each selected gRNA, order two oligonucleotides - the sense and antisense of the guide sequence. The BbsI restriction site overhangs (depends on the plasmid) are as follows:Fw oligo: 5’-CACC[G]”guide_sense_sequence”-3’Rv oligo: 5’-AAAC”guide_antisense_sequence”[C]-3’Resuspend each oligo in distilled water to 100µM.Note: only add the G and the C in square brackets if the guide doesn't start with a G. This is necessary for optimal transcription initiation from the U6 promoter.Typically, we design two gRNAs and test the cutting efficiency before the HDR experiment.Design of ssDNA Oligo HDR donor templateWe use a mix of up to 4 HDR donor ssDNA Oligos (100nt long) depending on the targeted mutation, the gRNA binding site and the PAM sequence.We will design the donor OligosCloning of guide RNA in the pSpCas9(BB)-2A-GFP vector (Addgene: px458)Step1. Oligo phosphorylation and annealing:To phosphorylate and anneal each pair of oligos, combine the following in a 0.2ml tube:1 µl oligo Fw (100µM in water)1 µl oligo Rv (100µM in water)1 µl 10X T4 Ligation Buffer (NEB)6.5 µl ddH2 O0.5 µl T4 PNK (NEB)Total volume = 10 µl totalIncubate37°C 30 min95°C 5 minRamp down to 25°C at 5°C/minStep 2. Digestion and ligation:1 µl pX330 or other backbone vector pSpCas9(BB)-2A-GFP (100ng/ul)2 µl of diluted oligo duplex from step 1 (diluted 1:250 in water)2 µl 10X FastDigest Buffer1 µl DTT (10mM)1 µl ATP (10mM)1 µl FastDigest BbsI (ThermoFisher)0.5 µl T7 DNA ligase (NEB)11.5 µl ddH2OTotal volume = 20 µlIncubate:37°C 5 min23°C 5 minCycle 6 times (total run time ~1h)Step 3. Transformation:•Add 5µl of ligation mix to 50 µl E.coli strain e.g One Shot competent cells•Incubate on ice for 20 minutes•Heat-shock the cells at 42°C for 45 seconds•Cool on ice for 2 minutes•Add 500µl of SOC media and incubate at 37°C with shaking for 30 minutes•Plate 100µl of the transformed bacteria on LB-agar + 100µg/ml ampicillin plates.•Incubate at 37°C overnight.Step 4. E coli colony screening for gRNAThe next morning, pick 5 colonies and incubate overnight in 5ml LB + 100µg/ml ampicilline at 37°C with shaking. After 8 hours, isolate the DNA with a DNA miniprep kit and send for Sanger sequencing with the hU6_Fw primer (5’-ACTATCATATGCTTACCGTAAC-3’).iPSC cultureReagents:•Essential 8 (Life Technologies, A14666SA)•Matrigel™ hESC-Qualified Matrix (Corning, cat. no. 354277)•Gentle Dissociation Solution (Stem Cell Technologies 07174)•Y-27632-HCl (Biorbyt, cat. no. orb154626)Thawing hiPSC:•hiPSC should be either generated in-house or can be obtained from available depositories e.g Wicell, Coriell or the Stanford CVI iPSC Biobank.•Remove vial from liquid nitrogen, place in 37 °C water bath until only a sliver of ice remains.Transfer the vial content dropwise (~1 mL) to a 15 mL conical tube filled with 4 ml of pre-warmed E8 supplemented with 2.5µM Y-27632 (E8 + iRock)•Centrifuge at 200 g for 4 min. Carefully aspirate the supernatant. Re-suspend the cell pellet in 2 mL of E8 + iRock and transfer to 1 well of a Matrigel-coated 6-well plate •Change media every 24 h with fresh E8. Cells should be 70-80% confluent in 3-4 days Passage of hiPSC:•Ideally cells should have reached 70-80% confluence in 3-4 days (adjust split ratio accordingly, typically 1/6-1/12).•Aspirate the E8 culture medium.•Add 2 mL per well of Gentle Dissociation Solution, incubate for 6-8 min at RT (in hood) •Whilst waiting, aspirate medium from Matrigel-coated plates and replace with 1 mL of E8Y.•Aspirate Gentle Dissociation Solution from each well.•Add 1 mL of E8 + iRock medium to the well. Gently detach the colonies by scraping with a serological pipette or a cell scraper. Add 6 mL of E8 + iRock for a 1:6 split.•Mix gently and transfer 1 mL in each well of the 6-well plate (2ml per well total volume). NOTE: We aim to keep the pluripotent cells in the logarithmic growth phase. Cells should not be allowed to become more than 90% confluent.TransfectionThe day before transfection, split the cells 1:2/1:3. Cell should be 50-60% confluent the next day: •Remove the medium•Wash once with PBS•Add 2.0ml Gentle Dissociation Solution•Incubate 5 min 37°C•Gently pipette up and down to dissociate the cells•Plate in a previously coated new well in E8 + iRock.On the day of transfection:•Replace media with fresh E8 media (1.0 mL/well).•For each well of a 6-well plate, prepare 4 separate reactions•Prepare the reactions by adding the reagents in the order shown:(i)Set up the CRISPR-Cas9-gRNA rxn:Mix A:o200 µL of Opti-MEMo10 µL of Lipofectamine Stem reagentMix B:o200 µL of Opti-MEMo1µg of CRISPR/Cas9 vector (pSpCas9(BB)-2A-GFP)Combine mix A & B – mix well and incubate for 15min @ RT(ii) A separate reaction is set up for the ssDNA donor oligos:Mix C:o200 µL of Opti-MEMo7.5 µL of RNAi max reagentMix D:o200 µL of Opti-MEMo 4 µg of ssDNA donor mix (if using 4 oligos, use 1µg each)Combine mix C & D – mix well and incubate for 15min @ RT•Add 400µl transfection mix of A+B and 400µl transfection mix of C+D to one well•Place the cells back in the incubator•After 4 hours, aspirate the transfection media from each well and replace with 2ml of fresh E8 supplemented with E8 + iRock•16-24h later, check the transfected cells under a fluorescent microscope for GFP+. Typically, the transfection efficiency is 5%-30% depending on the iPSC line. We FACs sort the cells 24-36h post transfection.FACS GFP+ cells•Aspirate the media•Wash once with PBS•Add 2.0 ml TrypLE express•Incubate 5-6 min 37°C until cells have detached – mix gently with a P1000 pipette to break down the cells to single cells•Add 4ml E8 + iRock•Transfer to a 15ml tube•Centrifuge 5 min @200g room temperature•Discard the supernatant and re-suspend the cells in 0.4 ml E8 + iRock•Filter the suspension through a 35-µm mesh Corning™ Falcon™ Test Tube with Cell Strainer Snap Cap•Prepare a 15ml collection tube containing 6ml E8 + iRock•Sort GFP-expressing cells using FACS sorter with a 100-µm nozzle – typically we sort 12,000 cells•Plate sorted cells in 6-well plates at a density of 2000 cells/well in E8 + 2.5µM iRcokIsolation of iPSC ClonesUsually 8-10 days after sorting, single iPSC colonies are large enough to be picked. We usually pick 30-40 clones that are clearly isolated from 3-6 wells of a 6-well plate.•Aspirate media and add 3ml of fresh E8 + iROCK media per well at least 2h before picking.•Manually pick individual iPSC clones (we use a P200 pipette set at 100µl) using a stereo-microscope located inside a cell culture hood, and transfer each clone to a 1.5ml tube.•Pipet up and down 2-3 times to partially dissociate the clone and transfer 90 µl of cell suspension into a separate well of a 24-well plate (Matrigel-coated) containing 500µL of E8+iRock. Savethe remaining 10µl of cells suspension for HDR screening by direct PCR (the samples can bestored at -20o C).•Allow the cells to attach for 24–48 h and then add 500µl E8 media. Feed the cells with fresh E8 media every other day.Genomic DNA isolationProtocol adapted from Phire Animal Tissue Direct PCR Kit (Thermo Fisher; Cat#: F140WH).•For each clone, dilute 0.5µl of DNA Release Additive in 19.5µl Dilution Buffer. We make a master mix for all the clones. Add 20µl of the master mix to each tube containing the ~10 µl of residual cell suspension from the clone picking step.•Mix well and incubate at room temperature for 10 minutes.•Then heat the samples at 98°C for 2 minutes.•Add 25µl of molecular grade water and centrifuge at top speed for 1 min at room temperature to allow for cell debris sedimentation. Use 3µl of the resulting solution as a template in the PCRreaction.Direct PCRPerform PCR using PrimeSTAR GXL DNA Polymerase (Clontech) and primers that amplify a region of 500nt around the target nucleotide. For each sample combine the following:13.5µl ddH2O (for 3µl template DNA)5µl PrimeSTAR GXL Buffer 5X2µl dNTP (2.5mM each)0.5 µl 10µM Fw Primer0.5 µl 10µM Rv Primer0.5 µl PrimeSTAR GXL DNA Polymerase3.0 µl of cell sampleTotal volume = 25 µlSet up the following program on the thermocycler:2 min 98°C10 sec 98°C15 sec 62°C20 sec 68°C(repeat X40)2 min 68°Chold 4°CSanger SequencingFirst, run 5µl of the PCR reaction on a 1% agarose gel to verify genomic DNA amplification.Once verified, the unpurified PCR samples (~20 µl) are sent out for sequencing using either the forward or the reverse primer.。
· 指南与共识·中国肾移植受者巨细胞病毒感染临床诊疗指南(2023版)中华医学会器官移植学分会 中国医师协会器官移植医师分会 中国医疗保健国际交流促进会肾脏移植学分会 【摘要】 近几年在实体器官移植(SOT )受者巨细胞病毒(CMV )感染诊疗领域,无论是诊断方法还是新型抗CMV 药物都有了一些新的进展,对CMV 感染的诊治产生了积极的影响。
为了进一步规范中国肾移植术后CMV 感染的管理,中华医学会器官移植学分会组织了国内多个学科相关领域专家,参考《中国实体器官移植受者巨细胞病毒感染诊疗指南(2016版)》和国内外已发表的最新文献和指南,制定了《中国肾移植受者巨细胞病毒感染诊疗指南(2023版)》,新版指南更新了CMV 流行病学,CMV 感染的危险因素和普遍性预防的研究进展,新增CMV 感染定义,细化CMV 血症和CMV 病的诊断标准,并对新型抗CMV 药物进行了介绍。
【关键词】 肾移植;实体器官移植;巨细胞病毒;感染;病毒血症;巨细胞病毒病;普遍性预防;抢先治疗【中图分类号】 R617, R373 【文献标志码】 A 【文章编号】 1674-7445(2024)03-0001-20Clinical diagnosis and treatment guidelines for cytomegalovirus infection in kidney transplant recipients in China (2023edition) Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplantation Physician of Chinese Medical Doctor Association, Branch of Kidney Transplantation of China International Exchange and Promotive Association for Medical and Health Care. *The First Affiliated Hospital of Xi 'an Jiaotong University , Xi 'an 710061, China Correspondingauthors:DingXiaoming,Email:***************.cnXueWujun,Email:******************.cn【Abstract 】 In recent years, there have been significant advances in the diagnosis and treatment of cytomegalovirus (CMV) infection in solid organ transplant (SOT) recipients, including diagnostic method and anti-CMV drugs. These advancements have had a positive impact on the management of CMV infection in SOT recipients. To further standardize the management of CMV infection after kidney transplantation in China, Branch of Organ Transplantation of Chinese Medical Association organized a multidisciplinary group of experts in relevant fields. They referred to the ‘Diagnosis and Treatment Guidelines for Cytomegalovirus Infection in Solid Organ Transplant Recipients in China (2016 edition)’ and the latest published literature and guidelines, resulting in the development of the ‘Clinical Diagnosis and Treatment Guidelines for Cytomegalovirus Infection in Kidney Transplant Recipients in China (2023 edition)’. The updated guideline includes CMV epidemiology, research progress on the risk factors and universal prevention of CMV infection, the definition for CMV infection, detailed diagnostic criteria for CMV viremia and CMV disease, as well as an introduction to new anti-CMV drugs.【Key words 】 Kidney transplantation; Solid organ transplantation; Cytomegalovirus; Infection; Viremia;Cytomegalovirus disease; Universal prevention; Preemptive therapyDOI: 10.3969/j.issn.1674-7445.2024096基金项目:国家自然科学基金(82370802、82170766、82270789、81970646);陕西省卫生健康肾脏移植科研创新平台(2023PT-06)执笔作者单位: 710061 西安,西安交通大学第一附属医院(丁小明);首都医科大学附属北京友谊医院(林俊);首都医科大学附属北京朝阳医院(胡小鹏);复旦大学附属中山医院(戎瑞明);西安交通大学第一附属医院(郑瑾)通信作者:丁小明,Email :***************.cn ;薛武军,Email :******************.cn第 15 卷 第 3 期器官移植Vol. 15 No.3 2024 年 5 月Organ Transplantation May 2024 巨细胞病毒(cytomegalovirus,CMV)是一种全球传播广泛的β-疱疹病毒,原发感染之后在体内会呈潜伏状态,当人体的免疫功能下降时病毒会被再激活。
•26何高燕,等miR-55通过靶向抑制SMAD3的表达抑制非小细胞肺癌细胞侵袭能力suppresson]J].Nut/tiox,2716,26(65):33-35.[16]LEE SUN EN,LIM JOO WEON,KIM HYEYOUNG.Achvatccproteis-1mediates docosabexaepoic acid-induced apoptosis oIhumao gastric ccoccs cells-J] ■Ann NY Acab Sci,O OC^,121:23-169.[26]ZHANG H,XU P,JIANG Y,et aU Gexomic,transc/ptomie,andepigexomic features diRerextiate gexes that are re/vvot Io muscular polyyasaturated fat/acibs is the commoo carp[J].Froot Gex-et,2616,16:22-228,[21]GIROS ANNA,GRZYBOWSKI MIKE,SOHN VANESSA R.Reg-ec Prev Res,2099,2(8):732-742.[22]KATAN T,CABALLERO-SOLARES A,TAYLOR RG,et aUEffect oI plant-based diets with varyino ratios oI36to<n3fattyacibs ox growth pebormadce,tissue compositiox,Jatty acid bdsyy-thesis and lipib-related gexe expressiox is Atlantic salmoo(Sal-mo sa/r t[J]•Comp Biochem Physiol Pa/D Gexomicr Pre-teomicr,2616,2(39):299-394.[23]DUAN YH,LI FN,LI LL,et aU Regulatiox oI physio/gdal func-tiox by proportiop oI o-6/2-3polyyasaturated fatty acibs-J].Natural Product Research and Developmext,2214,2:926-631.ulatiox oI colorectal cancer cell apoptosis by the n-3polyyasatu-(编校:张西敏) rated fatty acibs doccnaPexaeqoic and eicosapextaedoic t J].Cano-miR-55通过靶向抑制SMAD5的表达抑制非小细胞肺癌细胞侵袭能力何高燕,罗晓斌,赵勇,罗丽miR-103inhibits the invasion of non-small cell lung cancer cells by targeting inhibition of SMAD3expressiovHE Gaoyon,LUO Xiaobis,ZHAO Yony,LUO LlDepartment of'Respiratory and Critical Medicine,Suining City Central Hospital,Sichuan Suining626000,China.【Abstract】Objective:To investigate the effect of miR-55Braetiny the1011/1/0of SMAD3expression on theinvvsive abi/ty of non-small cell luny cancec cefs.Methods:The expression levels of miR-55and SMAD3in30oon-small cell luny caocer tissues and aPjacent tissues were deBcted by qRT-PCR and their000/1/00were ana-Uzed.The target geoe predichon site was used to predict the potenUal target geoe SMAD3of miR-145,which wasverified by the dual luciferase mpo/er gene assay.The tmnsfected cells of miR-55mimics,miR-55inhibitoc,siRNA SMAD3and related controls were Bansfected into oon-small cell luny cahcec A549cells by cell tmnsfechonexperiments j Trauswell assay was used to detect the iovvsive ability of A549cefs after tmnsfechon.The effect ofmiR-55on the expression of SMAD3protein was up-!011//0or dowo-1011//0in A549cells by Western b/t.Results:The results of qRT-PCR showed that miR-55was dowo-regumBq and SMAD3was highlo expressed inoon-small cell luuy cancec tissues,and the expression levels of both were hegakvelo00^//0.Taraet gene yredic-tion and vvhbation experiments showed that miR-55can specificaho bind to the3'-UTR of SMAD3,which was ataraet gene of miR-55.Western b/t analysis showed that tmnsfechon of miR-55mimics signi/cantlo decreasedthe expression of SMAD3proteih(P<0.001):and tmnsfechon of miR-55inhib/oc signi/cantlo iocmased the ep-pression of SMAD3protein(P<0.01).Tmoswef in vitro iovvsion assay showed that the transfected miR-145mimicgropp signi/cantlo reduced the iovvsive abi/ty of A549cells compared with the control groxa(P<0.001):and thetransfected miR-55inhibitor groxa signi/cantlo iocmased the invvsive abi/ty of A549cells(P<0.05).Comparedwith the control gropp,the iovvsive ability of khochdowh of SMAD3expressiny cells was weabened(P<0.001):The iovvsive abi/ty of co-transfected siRNA SMAD3and miR-55mimics A549cells was weaker than that ofkhochdowo of SMAD3alone(P<0.05).There was co significaot diderence in the iovvsive abi/ty of co-transfected【收稿日期】2629-93-92【基金项目】四川省卫生和计划生育委员会资助项目(编号:17pj937,5PJ499)【作者单位】遂宁市中心医院呼吸与危重症医学科,四川遂宁626009【作者简介】何高燕(192-),女,四川自贡人,硕士,医师,主要从事肺癌、肺纤维化及慢阻肺的诊疗工作。
第二章Mimi本教程的第二个例子中,我们将为你展示Mimics的一些基本功能,所要讨论的主题如下:●打开工程Opening the Project●窗口化Windowing●二值化Thresholding●区域增长Region Growing●建立3D表示Creating a 3D representation●显示3D表示Displaying a 3D representation●STL+过程STL+ Procedures●生成STL文件Generating a STL file●RP分层过程RP Slice procedures●生成一个轮廓文件Generating a contour file●生成支持文件Generating supports●结果视图View of the end result1.打开工程在文件菜单栏中,选择打开工程选项(或者直接用快捷键Ctrl+O),打开对话框中将显示工作目录中所有工程,双击打开mimi.mcs文件。
所有的图片都被打开并显示在三个视图中,右边视图是轴视图(xy-view或者axial view),左侧上面的视图是前视图(xz-view或者coronal view),左侧下面的视图是侧视图(yz-view或者sagittal view)。
不同颜色的交叉线代表了每个视图的等高线(contour lines),每条指示线能够标记相关视图的切片。
你可以在任意视图的CT图片的任意位置直接用鼠标点击你想要操作的位置,交叉线的位置将会到达你所点的位置,所有试图将更新显示为相关的切片。
如果视图中有些方位标记有错需要修改,在File > Change Orientation中打开窗口你可以通过右键鼠标选择正确的方位。
在菜单栏View > Indicators中可以选择分别关闭刻度线(Trick Marks)、交叉线(Intersection Lines)、分片位置(Slice Position)、方位字符(Orientation strings)指示器。
Artificial intelligence AI has become an integral part of modern society,offering numerous benefits that have transformed various sectors.Here are some of the key advantages of AI that can be highlighted in an English essay:1.Efficiency and Productivity:AI systems can process large amounts of data and perform tasks much faster than humans.This increased efficiency leads to higher productivity in industries such as manufacturing,where AI can automate repetitive tasks.2.Accuracy:AI algorithms are designed to minimize errors.In fields like healthcare,AI can assist in diagnosing diseases with high accuracy by analyzing medical images and patient data.3.Personalization:AI can analyze consumer behavior and preferences to provide personalized recommendations.This is evident in online shopping platforms and streaming services that suggest products and content based on individual user profiles.4.Innovation:AI drives innovation by enabling the development of new technologies and solutions.For example,AI has been instrumental in the advancement of selfdriving cars and smart home devices.5.Cost Reduction:By automating tasks,AI can reduce labor costs and operational expenses.Businesses can save on resources by relying on AI for tasks that would otherwise require human intervention.6.Enhanced Decision Making:AI can analyze vast amounts of data to provide insights that inform better decisionmaking.This is particularly valuable in finance,where AI can predict market trends and assist in risk management.7.Accessibility:AI technologies,such as voice assistants and translation services,make information and services more accessible to people with disabilities or those who speak different languages.8.Safety:In highrisk environments,such as mining or construction sites,AI can monitor conditions and alert workers to potential dangers,thereby improving safety.9.Environmental Impact:AI can optimize energy consumption in smart grids and buildings,contributing to a reduction in carbon emissions and promoting sustainability.cation:AI can provide personalized learning experiences for students,adapting to their pace and understanding to enhance the learning process.11.Healthcare Advancements:AI is used in drug discovery and development,which can expedite the process of finding new treatments and cures for various diseases.12.Predictive Analytics:AI can predict future trends and behaviors based on historical data,which is invaluable for planning and strategizing in business and government.In conclusion,the benefits of AI are vast and multifaceted,impacting nearly every aspect of life and work.As AI continues to evolve,its potential to improve our world becomes even more promising.。
高一科学探索英语阅读理解25题1<背景文章>The Big Bang Theory is one of the most important scientific theories in modern cosmology. It attempts to explain the origin and evolution of the universe. According to the Big Bang theory, the universe began as an extremely hot and dense singularity. Then, a tremendous explosion occurred, releasing an enormous amount of energy and matter. This event marked the beginning of time and space.In the early moments after the Big Bang, the universe was filled with a hot, dense plasma of subatomic particles. As the universe expanded and cooled, these particles began to combine and form atoms. The first atoms to form were hydrogen and helium. Over time, gravity caused these atoms to clump together to form stars and galaxies.The discovery of the cosmic microwave background radiation in 1964 provided strong evidence for the Big Bang theory. This radiation is thought to be the residual heat from the Big Bang and is uniformly distributed throughout the universe.The Big Bang theory has had a profound impact on modern science. It has helped us understand the origin and evolution of the universe, as well as the formation of stars and galaxies. It has also led to the development ofnew technologies, such as telescopes and satellites, that have allowed us to study the universe in greater detail.1. According to the Big Bang theory, the universe began as ___.A. a cold and empty spaceB. an extremely hot and dense singularityC. a collection of stars and galaxiesD. a large cloud of gas and dust答案:B。
A Method for the Rapid and Efficient Elution of NativeAffinity-Purified Protein A Tagged ComplexesCaterina Strambio-de-Castillia,†Jaclyn Tetenbaum-Novatt,†Brian S.Imai,‡Brian T.Chait,§andMichael P.Rout*,†The Rockefeller University,1230York Avenue,New York New York 10021-6399Received May 24,2005A problem faced in proteomics studies is the recovery of tagged protein complexes in their native and active form.Here we describe a peptide,Bio-Ox,that mimics the immunoglobulin G (IgG)binding interface of Staphylococcus aureus Protein A,and competitively displaces affinity-purified Protein A fusion proteins and protein complexes from IgG-Sepharose.We show that Bio-Ox elution is a robust method for the efficient and rapid recovery of native tagged proteins,and can be applied to a variety of structural genomics and proteomics studies.Keywords:Staphylococcus aureus •Protein A •affinity purification •proteomics •fusion proteinIntroductionProtein -protein interactions are central to the maintenance and control of cellular processes.The study of such protein -protein interactions has been greatly enhanced by fusion protein technology,wherein specific peptide or protein domain “tags”are fused to the protein of interest (generally at either its carboxyl-terminus or amino-terminus).These tags can facilitate the detection,increase the yield,and enhance the solubility of their associated proteins.1-3Most importantly,these fusion domains have been exploited to allow the single-step purification of the test protein either alone or in complexes with its in vivo binding partners.4-6The yield of these purifica-tion methods is often high enough to allow the identification of such binding partners by mass spectrometry.A commonly used affinity tagging method generates ge-nomically expressed Protein A (PrA)fusion proteins by modify-ing the coding sequence of the protein under study via PCR-directed approaches.7-9This method takes advantage of the ∼10nM binding affinity of PrA from S taphylococcus aureus for the constant region (Fc)of immunoglobulin G (IgG).10After purification on IgG-conjugated resins,PrA-tagged proteins or protein complexes are most commonly eluted from the resin using high or low pH conditions.These elution methods typically lead to the denaturation of the isolated proteins,the dissociation of complexes,and concomitant loss of activity.However,it is often desirable to recover soluble native protein or protein complexes.One method by which this can be achieved is by constructing a cleavable tag.Such tags carry a specific cleavage site for a protease placed proximal to the tagged protein,allowing the tag to be removed from the fusion protein.Proteases that are widely used for this purpose includeblood coagulation factors X (factor Xa),enteropeptidase (en-terokinase),alpha-thrombin,and the tobacco etch virus (TEV)protease.Nevertheless,this method has drawbacks.First,the literature is replete with reports of fusion proteins that were cleaved by these proteases at sites other than the canonical cleaving site.11-14Second,the removal of the tag destroys the ability to detect or further purify the protein of interest,necessitating the encumbrance of a second,tandem tag.15Here,we describe a rapid single step method for the efficient recovery of native and active PrA fusion proteins and protein complexes from IgG-Sepharose.This technique avoids the complications of having to use a protease and in addition has the advantage of retaining the original tag on the target protein after elution,permitting further purification steps and detection of the fusion protein in subsequent experiments.Our method takes advantage of a previously described peptide,termed FcIII,16which mimics the protein -protein binding interface of PrA for the hinge region on the Fc domain of human IgG.We modified FcIII by the addition of a biotin moiety to its amino-terminus to increase the peptide’s solubility while leaving its affinity for Fc intact s making it a more effective elution reagent.We termed this modified peptide,Bio-Ox.To investigate the properties of Bio-Ox,PrA-tagged proteins were isolated in their native state from yeast on an IgG-conjugated Sepharose resin,either alone or in combination with their in vivo interacting partners;the Bio-Ox peptide was then used to competitively displace the tagged proteins and elute them from the resin.The efficiency of elution was monitored by quantitatively comparing the amounts of proteins eluted to the amounts remaining on the resin under a variety of test conditions.We show that Bio-Ox elution is a robust method for the efficient and rapid recovery of native tagged proteins that can be applied to a variety of structural genomics and proteomics studies.*To whom correspondence should be addressed.Tel:+1(212)327-8135.E-mail:rout@.†Laboratory of Cellular and Structural Biology,Box 213.‡Proteomics Resource Center,Box 105.§Laboratory of Mass Spectrometry and Gaseous Ion Chemistry,Box 170.2250Journal of Proteome Research 2005,4,2250-225610.1021/pr0501517CCC:$30.25©2005American Chemical SocietyPublished on Web10/08/2005Experimental SectionPeptide Synthesis,Oxidation and Cyclization.Peptides were synthesized using standard Fmoc protocols.Typical deprotec-tion times with20%piperidine were2times10min and typical coupling times with4-10-fold excess of amino acids over resin were2to6h.Small batches of peptides were made on a Symphony synthesizer(Protein Technologies,Inc.),while larger batches were made manually.Peptides were cleaved from the resin using94.5%trifluoroacetic acid, 2.5%water, 2.5% ethanedithiol and1%triisopropylsilane for3h at25°C.The solubilized peptides were precipitated with10volumes of cold tert-butyl methyl ether and the precipitated peptide was washed several times with ether prior to air-drying.The air-dried peptide was dissolved in20%acetonitrile in water to approximately0.5mg/mL,the pH was adjusted to8.5using sodium bicarbonate and the peptide was allowed to air oxidize overnight to promote cyclization.The progress of cyclization was monitored by mass spectrometry.The cyclized crude peptide was purified using standard preparative reversed phase HPLC using a Vydac218TP1022C18column.Peptide Solubility.Eluting peptides were suspended at a concentration of440µM(0.77mg/mL for BioOx;0.67mg/mL for FcIII),in peptide buffer by extensive vortexing.The peptide concentration was verified by measuring the OD280nm of each solution(extinction coefficient:1OD280nm)0.13mg/mL).The peptide solutions/suspensions were then combined with equal amounts of a100mM buffer to obtain∼220µM peptide at a range of pH values(buffers:Na-Acetate pH4.8,Na-Citrate pH 5.4,Na-Succinate pH5.8,Na-MES pH6.2,BisTris-Cl pH6.5, Na-HEPES pH7.4,Na-TES pH7.5,Tris-Cl pH8.3,Na-CAPSO pH9.6).Samples were incubated at room temperature with gentle agitation for20min,and then insoluble material was removed by centrifugation at21000×g max for20min at25°C.The concentration of peptide in each remaining superna-tant was determined by measuring its OD280nm.To determine the maximum solubility of each peptide,the peptides were dissolved to saturation in peptide buffer by extensive vortexing and incubation with stirring at25°C overnight.Insoluble material was removed by centrifugation at15000×g for15min at25°C and the amount of dissolved peptide was measured directly by amino acid analysis.Peptide Competitive Displacement of Bound Recombinant PrA from IgG-Sepharose.Recombinant PrA(280µg;6.7nmol) from S.aureus(Pierce)was dissolved in1mL TB-T[20mM HEPES-KOH pH7.4,110mM KOAc,2mM MgCl2,0.1%Tween-20(vol/vol)]and added to280µL of packed pre-equilibrated Sepharose4B(Amersham Biosciences)conjugated with affinity-purified rabbit IgG(ICN/Cappel; 1.87nmoles IgG).After incubation on a rotating wheel overnight at4°C,the resin was washed twice with1mL TB-T,twice with1mL TB-T containing 200mM MgCl2,and twice with1mL TB-T.After the final wash, the resin was divided evenly into14equal aliquots.The peptide was dissolved in peptide buffer at concentrations ranging between0and440µM peptide.Aliquots of400µL of the appropriate peptide solution was added to each PrA-IgG-Sepharose containing tube,and the tubes were then incubated on a rotating platform for3h at4°C followed by1h at25°C. After displacement of bound PrA from the IgG-Sepharose,the resin was recovered by centrifugation on a Bio-Spin column (BioRad),and resuspended in one-bed volume of sample buffer.Samples were separated by SDS-PAGE.Yeast Strains.Strains are isogenic to DH5alpha unless otherwise specified.All yeast strains were constructed using standard genetic techniques.C-terminal genomically tagged strains were generated using the PCR method previously described.7,17Affinity Purification of Proteins and Protein Complexes on IgG-Sepharose.The protocol for the purification of PrA-containing complexes was modified from published methods.18-20For the purification of Kap95p-PrA,yeast cytosol was prepared essentially as previously described.21,22Kap95p-PrA cytosol was diluted with3.75volumes of extraction buffer 1[EB1:20mM Hepes/KOH,pH7.4,0.1%(vol/vol)Tween-20, 1mM EDTA,1mM DTT,4µg/mL pepstatin,0.2mg/mL PMSF]. The diluted cytosol was cleared by centrifugation at2000×g av for10min in a Sorvall T6000D tabletop centrifuge and at 181000×g max for1h in a Type80Ti Beckman rotor at4°C.10µL bed volume of IgG-Sepharose pre-equilibrated in EB1was added per0.5mL of cytosol and the binding reaction was incubated overnight at4°C on a rotating wheel.The resin was recovered by centrifugation at2000×g av for1min in a Sorvall T6000D tabletop centrifuge,transferred to1.5mL snap-cap tubes(Eppendorf),and washed6times with EB1without DTT. For the purification of Nup82p-PrA,cells were grown in Whickerham’s medium21to a concentration of4×107cells/ mL,washed with water and with20mM Hepes/KOH pH7.4, 1.2%PVP(weight/vol),4µg/mL pepstatin,0.2mg/mL PMSF, and frozen in liquid N2before being ground with a motorized grinder(Retsch).Ground cell powder(1g)was thawed into10 mL of extraction buffer2[EB2;20mM Na-HEPES,pH7.4,0.5% TritonX-100(vol/vol),75mM NaCl,1mM DTT,4µg/mL pepstatin,0.2mg/mL PMSF].Cell lysates were homogenized by extensive vortexing at25°C followed by the use of a Polytron for25s(PT10/35;Brinkman Instruments)at4°C.Clearing of the homogenate,binding to IgG-Sepharose,resin recovery and washing was done as above except that10µL of IgG-Sepharose bed volume was used per1g of cell powder and EB2without DTT was used for all the washes.Elution of the PrA tagged complexes was performed as described below.Peptide Elution of Test Proteins and Protein Complexes and Removal of Peptide by Size Exclusion.Kap95p-PrA or Nup82p-PrA bound IgG-Sepharose resin was recovered over a pre-equilibrated Bio-Spin column(BioRad)by centrifugation for1min at1000×g max.Three bed-volumes of440µM(unless otherwise indicated in the text)of eluting peptide in peptide buffer were added per volume of packed IgG Sepharose resin. The elution was carried out for various times(as indicated in the text)at either4°C or at25°C.When elution was complete, the eluate was recovered over a Bio-Spin column.Finally,the resin was washed with one bed-volume of elution buffer to displace more eluted material from the resin and the wash was pooled with the initial eluate.The peptide was removed by filtration of the eluate over a micro spin G25column(Amer-sham Biosciences)as described by the manufacturer.Kap95p-Nup2p in Vitro Binding Experiments.To demon-strate in vitro binding of proteins after elution from the resin, Kap95p-PrA from0.3mL of yeast cytosol was affinity-purified on17.5µL of packed IgG-Sepharose and eluted with52.5µL of440µM Bio-Ox for2.5h at4°C followed by1h at25°C. The resulting sample(total volume88µL)was mixed with0.1µL of E.coli total cell lysate containing Nup2p-GST(generous gift from David Dilworth and John Aitchison23)and brought to a total volume of500µL with TB-T,1mM DTT,4µg/mL pepstatin,0.2mg/mL PMSF.Controls were set up in the absence of either Kap95p-PrA or Nup2p-GST.The samples were incubated at25°C for30min after which40µL of packed,pre-Native Elution of PrA-Tagged Proteins research articlesJournal of Proteome Research•Vol.4,No.6,20052251equilibrated glutathione-Sepharose 4B resin (Amersham Bio-sciences)was added per sample and the incubation was continued at 4°C for 1h.After nine washes with 1mL of TB-T,1mM DTT,4µg/mL pepstatin,0.2mg/mL PMSF,at 25°C,the resin was recovered on Bio-Spin columns as described above and bound material was eluted with 40µL of sample buffer.The samples were resolved on SDS-PAGE alongside an aliquot of input peptide-eluted Kap95p-PrA.To demonstrate the recovery of in vitro reconstituted protein complexes from the resin,Kap95p-PrA from 0.3mL of yeast cytosol was affinity-purified on 10µL of packed IgG-Sepharose and the washed resin was equilibrated in TB-T,1mM DTT,4µg/mL pepstatin,0.2mg/mL PMSF.This pre-bound Kap95p-PrA was mixed with 50µL of E.coli total cell lysate containing Nup2p-GST in a total volume of 1mL of TB-T,1mM DTT,4µg/mL pepstatin,0.2mg/mL PMSF.A mock control experiment was set up in the absence of Nup2p-GST.The binding reaction was carried out for 1h at 4°C and the resin was washed 2times with 1mL of TB-T,2times with 1mL of TB-T containing 100µM ATP and 3times with peptide buffer (all washed were without DTT).Bound material was eluted with 30µL of 440µM Bio-Ox in peptide buffer at 4°C for 2.5h at 4°C followed by 1h at 25°C.Samples were resolved by SDS-PAGE.Figure 1.Addition of a Biotin moiety to the FcIII peptide does not alter the ability of the peptide to competitively displace bound PrA from IgG-Sepharose.(a)Primary sequence and chemical structure of the biotinylated FcIII peptide,Bio-Ox.(b)220µM suspensions of peptides were prepared in buffers of different pHs,and allowed to solubilize.The material remaining in the buffer after centrifugation is plotted for Bio-Ox (closed triangles,black trend line )and FcIII (open circles,gray trend line ;dashed horizontal line represents the starting 220µM level .(c)Increasing amounts of Bio-Ox (closed triangles )and FcIII (open diamonds )were used to competitively displace recombinant PrA from IgG-Sepharose.The amounts of PrA left on the resin after elution were resolved by SDS-PAGE alongside known amounts of PrA standards.The data are displayed on logarithmic scale on both axes.Data are displayed as a %recovery relative to the input PrA amount (i.e.,PrA amount remaining bound in the absence of eluting peptide).Linear regression for both data sets was used to calculate the IC50.research articlesStrambio-de-Castillia et al.2252Journal of Proteome Research •Vol.4,No.6,2005Quantitation and Image Analyses.Band intensities were quantified with the Openlab software (Improvision),and the data was plotted using Excel (Microsoft).Results and DiscussionDesign of the PrA Mimicking Peptide.The hinge region on the Fc fragment of immunoglobulin G (IgG)interacts with Staphylococcus aureus Protein A (PrA).This region was also found to be the preferred binding site for peptides selected by bacteriophage display from a random library.16The specific Fc binding interactions of a selected 13amino acid peptide (termed FcIII),were shown to closely mimic those of natural Fc binding partners.We reasoned that this peptide could be used to efficiently displace PrA tagged proteins from IgG-conjugated affinity resins.Initial trials with FcIII determined that,although it functioned as an eluant,it exhibited a strong tendency to aggregate and its solubility under physiological conditions was not sufficient for many practical purposes,leading to low yields and nonreproducible results.As the high peptide concentrations needed for elution are outside the conditions for which the FcIII peptide was designed,we synthesized several modified peptides based on FcIII,with the specific aim of increasing their solubility and decreasing their degree of aggregation under conditions that would be useful for the isolation of proteins and protein complexes.Among the different alternatives,the most efficient in the displacement of bound PrA-tagged Kap95p from IgG-Sepharose was a peptide in which the amino-terminus of the original FcIII peptide wasFigure 2.Bio-Ox can be used to efficiently compete bound PrA-tagged proteins and protein complexes from IgG-Sepharose in a temperature-dependent fashion.(a )Kap95p-PrA/Kap60p was affinity-purified on IgG-Sepharose from logarithmically growing yeast cells.440µM Bio-Ox was used to competitively displace the bound tagged proteins from the IgG-Sepharose resin.The elution reaction was carried out for the times indicated.At the end of the incubation time eluted proteins (E )and proteins remaining bound to the resin (B )were resolved on SDS-PAGE.(b )Kap95p-PrA (closed squares)and Nup82p-PrA (open squares )were affinity-purified on IgG-Sepharose from logarithmically growing yeast cells and eluted as described above.The amounts of eluted versus resin-bound protein was quantified using the OpenLab software and the elution efficiency for each time point is presented as the percentage of eluted material over the total amount of bound plus eluted material (%eluted).(c )440µM Bio-Ox was used to elute Kap95p-PrA or Nup82p-PrA for 1h at 4°C or 25°C as indicated.Native Elution of PrA-Tagged Proteinsresearch articlesJournal of Proteome Research •Vol.4,No.6,20052253modified by the addition of a Biotin moiety (data not shown).We termed this peptide Bio-Ox (Figure 1,panel a).The solubility of Bio-Ox was measured directly by amino acid analysis and was shown to be ∼3-fold greater than the solubility of FcIII at pH 7.4.In addition,comparison of the solubility of both peptides over a range of pHs indicated that the Bio-Ox was considerably more soluble than FcIII at all but the most extreme pHs tested;importantly,Bio-Ox is very soluble across the full physiological range of pHs (Figure 1,panel b).To determine whether the addition of the Biotin moiety could have altered the inhibiting ability of the peptide,we measured the inhibition constant for Bio-Ox and found it to be comparable with the reported K i for FcIII (∼11nM;data not shown).We then measured the IC 50for competitive displacement for FcIII and Bio-Ox,under conditions in which both were soluble.For this test,commercially available recom-binant PrA from S.aureus was first bound to IgG-Sepharose and then increasing concentrations of the peptide were used to displace the bound PrA from the immobilized IgG (Figure 1,panel c).The apparent IC 50was found to be 10.4(3.2µM for FcIII and 9.8(2.6µM for Bio-Ox (mean value of four independent trials (standard deviation of the mean).Taken together,Bio-Ox appears to be as efficient as FcIII at binding to the F c portion of antibodies and competing for this site with Protein A,but is far more soluble in physiologically compatible buffers,a key requirement for an efficient elution peptide (Figure 3).Experimental Design of the Competitive Elution Procedure.The principle of the method is as follows;genomically PrA-tagged proteins of interest are expressed in yeast and affinity isolated on IgG-conjugated Sepharose resin.Depending on the conditions used for lysis and extraction,the test protein can be recovered in native form either in isolation or in complexes with protein partners.After binding,the resin is recovered by centrifugation and washed extensively to remove unbound material.The bound material is competitively displaced from the IgG-Sepharose resin by incubation with 440µM Bio-Ox peptide in peptide buffer for 2h at 4°C.Finally,the peptide is rapidly (<1min)removed from the eluted sample by fraction-ation over a size exclusion spin column.Given a typical protein of average abundance,1-10µg of pure protein can be recovered from 1g of cells using this method.Figure 3.Elution of Kap95-PrA/Kap60p is dose dependent.(a )Kap95p-PrA was affinity-purified on IgG-Sepharose from loga-rithmically growing yeast cells and eluted using increasing concentrations of Bio-Ox peptide as indicated.(b )The elution efficiency measured as described in Figure 2was plotted versus the peptide concentration in logarithmic scale as indicated.Figure 4.Eluted Kap95p-PrA/Kap60complex retains its biological activity.(a )Kap95p-PrA was prepared by affinity purification followed by Bio-Ox peptide elution (Kap95-PrA eluate ).Three binding reactions were then set up containing eluted Kap95p-PrA and Nup2p-GST bacterial lysate,Kap95p-PrA alone or Nup2p-GST alone.At the end of the incubation,Nup2p-GST was affinity-purified on glutathione-Sepharose and the immobilized material was eluted from the resin with sample buffer and resolved on SDS -PAGE (GST bound ).(b )Kap95p-PrA was immobilized on IgG-Sepharose and incubated with (+)or without (-)bacterial lysate containing Nup2p-GST.The resulting material was eluted using Bio-Ox.Eluate (E )and resin bound (B )material was resolved on SDS-PAGE.*,indicates a Nup2p breakdown product.Table 1.Elution Efficiency for PrA Tagged Nupsname of nup%yieldNup53p 56Nup59p 81Nup84p 88Nup85p 81Nic96p 76Nsp1p 99Nup1p 99Nup120p 69Nup157p 82Nup159p 53Nup170p 80Nup192p 76Gle2p 90research articlesStrambio-de-Castillia et al.2254Journal of Proteome Research •Vol.4,No.6,2005To explore the characteristics of Bio-Ox elution under conditions that preserve native protein complexes,we chose to work with the yeast karyopherin Kap95p-PrA/Kap60p com-plex,24and with the yeast nucleoporin Nup82p-PrA/Nsp1p/ Nup159p complex.25,26This choice was dictated by our interest in the structure and function of the yeast nuclear pore complex (NPC).17,27Optimization of the Elution Conditions.An elution time course for Kap95p-PrA/Kap60p and Nup82p-PrA from IgG-Sepharose at4°C is shown in Figure2,panels a and b.In both cases,the elution was virtually complete after2h at4°C.The largest difference in elution efficiency between the two test proteins was found at the earlier time points.Thus,more than 50%of initially bound Kap95p-PrA was displaced by10min, while it took∼1h to obtain the same result with Nup82p-PrA. We also determined the temperature dependence of the elution process(Figure2,panel c).Elutions of Kap95p-PrA and Nup82p-PrA with Bio-Ox,for1h were compared at4°C and 25°C(Figure2,panel c),showing that elution was improved at25°C over4°C for both test proteins.These various factors underscore the need to conduct appropriate test experiments to determine the optimal conditions for any given application. For example,elution for shorter periods and at4°C is preferable when the proteins under study are sensitive to denaturation,dissociation or proteolytic degradation.We also tested the dependence of elution efficiency upon Bio-Ox concentration.For this test,Kap95p-PrA bound to IgG-Sepharose was competitively displaced using increasing amounts of Bio-Ox peptide for4h at4°C.(Figure3).Bio-Ox peptide displaced IgG-Sepharose bound PrA tagged Kap95p with an apparent IC50of60.8µM.For practical purposes,the protocol we use in most cases takes advantage of the high solubility of Bio-Ox to obtain maximally efficient elutions,utilizing a concentration of440µM of Bio-Ox peptide for2h at4°C.To test the general applicability of the method,we performed peptide elution experiments using a series of PrA tagged proteins that were available in our laboratories.17The yield for these proteins was in all cases>50%and in most cases was >80%(average yield78%(14%;Table1).Eluted Proteins Retain their Biological Activity.The trans-location of macromolecules between the nucleus and cytosol of eukaryotic cells occurs through the NPC and is facilitated by soluble transport factors termed karyopherins(reviewed in ref28).Nucleoporins that contain FG peptide repeats(FG Nups)function as binding sites for karyopherins within the NPC.One example of an FG Nup-karyopherin interaction is represented by the binding of the Kap95p/Kap60p complex to Nup2p,29an interaction that requires both karyopherins to be natively folded.30,31We took advantage of this interaction to demonstrate that the Bio-Ox eluted Kap95p-PrA/Kap60p com-plex retains its biological activity and is able to bind Nup2p in vitro(Figure4,panel a).In this test,Kap95p-PrA was affinity-purified and eluted from IgG-Sepharose as described above. The eluate was incubated with whole cell lysate from E.coli expressing Nup2p-GST,23and GST-tagged Nup2p was isolated over gluthatione-Sepharose resin.As a control,the same experiment was performed either in the absence of Nup2p-GST containing bacterial lysate or in the absence of Kap95p-PrA eluate.As shown,Nup2p-GST binds specifically and directly to the peptide-eluted Kap95p-PrA/Kap60p complex. This result is consistent with reported data and demonstrates that elution with Bio-Ox does not alter the native state and biological activity of Kap95p-PrA.Moreover,the apparent equimolar stoichiometry of the Nup2-GST/Kap95p-PrA/Kap60p complex indicates that essentially all of the peptide eluted karyopherins were in their native,active conformation.This result underscores the usefulness of this method for the preparation of native protein samples.The method can also be used for in vitro reconstitution experiments of biologically relevant protein-protein interac-tions of interest.For this test,Kap95p-PrA was affinity isolated on IgG-Sepharose,Nup2p-GST was bound to the immobilized Kap95p-PrA and then the reconstituted complex was competi-tively displaced from the resin by Bio-Ox peptide elution(Figure 4,panel b).This shows that the method can be used in vitro to study protein-protein interactions using purified compo-nents.ConclusionWe have used the Bio-Ox technology extensively in our laboratories for a wide variety of applications including:(1) the semipreparative purification of∼30PrA-tagged natively folded Nups for the determination of their sedimentation coefficient over a sucrose velocity gradient(S.Dokudovskaya, L.Veenhoff,personal communication);(2)the isolation of yeast cyclins and cyclin-Cdk associated proteins;32(3)the semi-preparative purification of enzymatically active Dpb4p-PrA chromatin remodeling/histone complexes;33and(4)the study of the in vitro binding property of proteins of interest using blot and resin binding experiments.34Thus,this method should be generally applicable to the native purification of most other proteins and protein complexes.Acknowledgment.We are very grateful to David Dil-worth and John Aitchison for the generous gift of bacterially expressed Nup2p-GST.We are deeply indebted to Rosemary Williams for her skilled technical assistance throughout the course of this study and to all members of the Rout and Chait laboratories and of the Proteomic Research Center,past and present,for their continual help and unwavering support.We are particularly grateful to Markus Kalkum,Bhaskar Chan-drasekhar,Svetlana Dokudovskaya and Liesbeth Veenhoff.This work was supported by grants from the American Cancer Society(RSG-0404251)and the NIH(GM062427,RR00862,and CA89810).References(1)Uhlen,M.;Forsberg,G.;Moks,T.;Hartmanis,M.;Nilsson,B.Fusion proteins in biotechnology.Curr.Opin.Biotechnol.1992, 3(4),363-369.(2)Nygren,P.A.;Stahl,S.;Uhlen,M.Engineering proteins to facilitatebioprocessing.Trends Biotechnol.1994,12(5),184-188.(3)Baneyx,F.Recombinant protein expression in Escherichia coli.Curr.Opin.Biotechnol.1999,10(5),411-421.(4)LaVallie,E.R.;McCoy,J.M.Gene fusion expression systems inEscherichia coli.Curr.Opin.Biotechnol.1995,6(5),501-506.(5)Nilsson,J.;Stahl,S.;Lundeberg,J.;Uhlen,M.;Nygren,P.A.Affinity fusion strategies for detection,purification,and im-mobilization of recombinant proteins.Protein Expr.Purif.1997, 11(1),1-16.(6)Einhauer,A.;Jungbauer,A.The FLAG peptide,a versatile fusiontag for the purification of recombinant proteins.J.Biochem.Biophys.Methods2001,49(1-3),455-465.(7)Aitchison,J. D.;Blobel,G.;Rout,M.P.Nup120p:a yeastnucleoporin required for NPC distribution and mRNA transport.J.Cell Biol.1995,131(6Pt2),1659-1675.(8)Grandi,P.;Doye,V.;Hurt,E.C.Purification of NSP1revealscomplex formation with‘GLFG’nucleoporins and a novel nuclear pore protein NIC96.EMBO J.1993,12(8),3061-3071.(9)Stirling,D.A.;Petrie,A.;Pulford,D.J.;Paterson,D.T.;Stark,M.J.Protein A-calmodulin fusions:a novel approach for investigat-ing calmodulin function in yeast.Mol.Microbiol.1992,6(6),703-713.Native Elution of PrA-Tagged Proteins research articlesJournal of Proteome Research•Vol.4,No.6,20052255。
DOI: 10.1126/scitranslmed.3002842, 95ra73 (2011);3 Sci Transl Med , et al.Michael Kalos and Can Establish Memory in Patients with Advanced Leukemia T Cells with Chimeric Antigen Receptors Have Potent Antitumor EffectsEditor's Summarythe potential for CAR-modified T cells to bring cancer therapy up to speed.treatment had complete remission of their leukemia. Although this is early in the clinical study, these results highlight scale with a second exposure to CLL cells. Indeed, two of the three CLL patients who underwent the CAR T cell CAR T cells persisted with a memory phenotype, which would allow them to respond more quickly and on a larger these CAR T cells expanded >1000-fold, persisted for more than 6 months, and eradicated CLL cells. Some of these allowing for much broader cellular targeting than is obtained with normal T cells. After transfer into three CLL patients,receptor could activate T cells in response to CD19 in the absence of major histocompatibility complex restriction, specific intracellular signaling domain. The resulting chimeric −specific costimulatory domain and a T cell −both a T cell bind in a restricted manner to the CD19 protein (which is found solely on normal B cells and plasma cells) attached to The CAR T cells used in this study expressed an antigen receptor that consists of antibody binding domains that as reflected by decreased numbers of B cells and plasma cells and the development of hypogammaglobulinemia.tumor cells after transfer into patients; they also mediated cancer remission. Innocent bystanders were also targeted, chronic lymphocytic leukemia (CLL) (a B cell cancer). The designer T cells not only expanded, persisted, and attacked modified T cells to express a chimeric antigen receptor (CAR) to yield so-called CAR T cells that specifically target . have genetically et al cells to the tumor and maintaining these cells in patients remains challenging. Now, Kalos harness the power of the immune system to fight cancers such as leukemia; however, targeting functional immune T to healthy tissues, such as infection or cancer, and then try to deter dangerous activity. Researchers have long sought As members of the body's police force, cells of the immune system vigilantly pursue bad actors that harmGo CAR-Ts in the Fast Lane/content/3/95/95ra73.full.html can be found at:and other services, including high-resolution figures,A complete electronic version of this article /content/suppl/2011/08/08/3.95.95ra73.DC1.htmlcan be found in the online version of this article at: Supplementary Material/about/permissions.dtl in whole or in part can be found at:article permission to reproduce this of this article or about obtaining reprints Information about obtaining last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue (print ISSN 1946-6234; online ISSN 1946-6242) is published weekly, except the Science Translational Medicine o n F e b r u a r y 20, 2012s t m .s c i e n c e m a g .o r g D o w n l o a d e d f r o mL E U K E M I AT Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaMichael Kalos,1,2*Bruce L.Levine,1,2*David L.Porter,1,3Sharyn Katz,4Stephan A.Grupp,5,6 Adam Bagg,1,2Carl H.June1,2†Tumor immunotherapy with T lymphocytes,which can recognize and destroy malignant cells,has been limited by the ability to isolate and expand T cells restricted to tumor-associated antigens.Chimeric antigen receptors(CARs) composed of antibody binding domains connected to domains that activate T cells could overcome tolerance by allowing T cells to respond to cell surface antigens;however,to date,lymphocytes engineered to express CARs have demonstrated minimal in vivo expansion and antitumor effects in clinical trials.We report that CAR T cells that target CD19and contain a costimulatory domain from CD137and the T cell receptor z chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia(CLL).The engineered T cells expanded>1000-fold in vivo,trafficked to bone marrow,and continued to express functional CARs at high levels for at least6months.Evidence for on-target toxicity included B cell aplasia as well as decreased numbers of plasma cells and hypogammaglobulinemia.On average,each infused CAR-expressing T cell was calculated to eradicate at least1000CLL cells.Furthermore,a CD19-specific immune re-sponse was demonstrated in the blood and bone marrow,accompanied by complete remission,in two of three patients.Moreover,a portion of these cells persisted as memory CAR+T cells and retained anti-CD19effector functionality,indicating the potential of this major histocompatibility complex–independent approach for the ef-fective treatment of B cell malignancies.INTRODUCTIONUsing gene transfer technologies,T cells can be genetically modified to stably express antibody binding domains on their surface that con-fer novel antigen specificities that are major histocompatibility com-plex(MHC)–independent.Chimeric antigen receptors(CARs)are an application of this approach that combines an antigen recognition domain of a specific antibody with an intracellular domain of the CD3-z chain or Fc g RI protein into a single chimeric protein(1,2). Trials testing CARs are presently under way at a number of academic medical centers(3,4).In most cancers,tumor-specific antigens are not yet well defined,but in B cell malignancies,CD19is an attractive tumor target.Expression of CD19is restricted to normal and malig-nant B cells(5),and CD19is a widely accepted target to safely test CARs.Although CARs can trigger T cell activation in a manner sim-ilar to an endogenous T cell receptor,a major impediment to the clin-ical application of this technology to date has been the limited in vivo expansion of CAR+T cells,rapid disappearance of the cells after in-fusion,and disappointing clinical activity(4,6).CAR-mediated T cell responses may be further enhanced with ad-dition of costimulatory domains.In a preclinical model,we found that inclusion of the CD137(4-1BB)signaling domain significantly increased antitumor activity and in vivo persistence of CARs com-pared to inclusion of the CD3-z chain alone(7,8).To evaluate the safety and feasibility for adoptive transfer of T cells gene-modified to express such CARs,we initiated a pilot clinical trial using autologous T cells expressing an anti-CD19CAR including both CD3-z and the 4-1BB costimulatory domain(CART19cells)to target CD19+malig-nancies.To date,we have treated three patients under this protocol. Some of the findings from one of these patients are described in(9), which reports that this treatment results in tumor regression,CART19 cell persistence,and the unexpected occurrence of delayed tumor lysis syndrome.Here,we show that the CART19cells mediated potent clinical antitumor effects in all three patients treated.On average,each infused CAR T cell and/or their progeny eliminated more than 1000leukemia cells in vivo in patients with advanced chemotherapy-resistant chronic lymphocytic leukemia(CLL).CART19cells underwent robust in vivo T cell expansion,persisted at high levels for at least6 months in blood and bone marrow(BM),continued to express func-tional receptors on cells with a memory phenotype,and maintained anti-CD19effector function in vivo.RESULTSClinical protocolThree patients with advanced,chemotherapy-resistant CLL were enrolled in a pilot clinical trial for CART19cell therapy.Figure1presents a summary of the manufacturing process for the gene-modified T cells (A)and the clinical protocol design(B).All patients were extensively pretreated with various chemotherapy and biologic regimens(Table1). Two of the patients had p53-deficient CLL,a deletion that portends poor response to conventional therapy and rapid progression(10). Each of the patients had a large tumor burden after the preparative1Abramson Cancer Center,University of Pennsylvania,Philadelphia,PA19104,USA.2De-partment of Pathology and Laboratory Medicine,University of Pennsylvania,Philadelphia, PA19104,USA.3Department of Medicine,University of Pennsylvania,Philadelphia,PA 19104,USA.4Department of Radiology,University of Pennsylvania,Philadelphia,PA19104, USA.5Department of Pediatrics,University of Pennsylvania,Philadelphia,PA19104,USA. 6Division of Oncology,Children’s Hospital of Philadelphia,Philadelphia,PA19104,USA.*These authors contributed equally to this work.†To whom correspondence should be addressed.E-mail:cjune@ o n F e b r u a r y 2 0 , 2 0 1 2 s t m . s c i e n c e m a g . o r g D o w n l o a d e d f r o mchemotherapy,including extensive BM infiltration(40to95%)and lymphadenopathy;UPN02also had peripheral lymphocytosis.There was a low abundance of T cells in the apheresis products(2.29to4.46%) (table S1)as well as likely impaired T cell activation,as has been shown previously in CLL patients(11).Additional details of the cell manufac-turing and product characterization for the CART19cell preparation for each patient are shown in table S1.All patients were pretreated1to 4days before CART19cell infusions with lymphodepleting chemo-therapy(Table1).A split-dose cell infusion schedule was used to address potential safety concerns related to the evaluation of a previously untested CAR that incorporated the4-1BB costimulatory signaling domain. In vivo expansion,persistence,and BM trafficking of CART19cellsOur preclinical data in two animal models,including mice bearing xenografts of primary human precursor-B acute lymphoblastic leuke-mia(7,8),indicated that CAR+T cells that express a4-1BB signaling domain expanded after stimulation with anti-CD3/anti-CD28mono-clonal antibody–coated beads(12)and had improved persistence com-pared to CAR+T cells lacking4-1BB.We developed a quantitative polymerase chain reaction(qPCR)assay to enable quantitative tracking of CART19cells in blood and BM.CART19cells expanded and persisted in the blood of all patients for at least6months(Fig.2, A and B).Moreover,CART19cells expanded1000-to10,000-fold in the blood of patients UPN01and03during the first month after infusion,reaching peak frequencies of10to>95%of circulating white blood cells in UPN01and03(Fig.2C).The peak expansion levels coincided with onset of the clinical symptoms after infusion in UPN01 (day15)and UPN03(day23).Furthermore,after an initial decay,which can be modeled with first-order kinetics,the CART19cell numbers stabilized in all three patients from days90to180after infusion (Fig.2B).The CART19cells also trafficked to the BM in all patients, albeit in5-to10-fold fewer numbers than observed in blood(Fig.2D). CART19cells had a log-linear decay in the BM in UPN01and03, with a disappearance half-life of~35days.Induction of specific immune responses in the peripheral blood and BM compartments after CART19infusion Peripheral blood(PB)and BM serum samples from all patients were collected and batch-analyzed to quantitatively determine cytokine levels.A panel of30cytokines,chemokines,and other soluble factors were assessed for potential toxicities and to provide evidence of CART19cell function.The full data set for all of the cytokines measured in each of the three patients through the date of thisapheresisSeed in gas-permeable bags.Transduction w/αCD19-41BBζvectorVector washout.Culture in gas-permeable bagsCulture in WAV EbioreactorHarvest, wash, concentrateCryopreserve final product ininfusible cryomediaCD3/28-positive selection ofT cells with anti-CD3/anti-CD28 mAb-coated magneticbeadsDay 0Day 0-1Day 3Day 5Harvest day(10 ±2)ABManufacture/cryopreservationFig.1.Schematic representation of the gene transfer vector and trans-gene,gene-modified T cell manufacturing,and clinical protocol design.(A)T cell manufacturing.Autologous cells were obtained via leukapher-esis,and T cells were enriched by mononuclear cell elutriation,washed, and expanded by addition of anti-CD3/CD28–coated paramagnetic beads for positive selection and activation of T cells.Residual leukemic cells were depleted.The lentiviral vector was added at the time of cell activation and was washed out on day3after culture initiation.Cells were expanded on a rocking platform device(WAVE Bioreactor System) for8to12days.On the final day of culture,the beads were removed by passage over a magnetic field and the CART19cells were harvested and cryopreserved in infusible medium.mAb,monoclonal antibody.(B)Clin-ical protocol design.Patients were given lymphodepleting chemo-therapy as described,followed by CART19infusion#1by intravenous gravity flow drip over a period of15to20min.The infusion was given using a split-dose approach over3days(10,30,and60%)beginning1to5days after completion of chemotherapy.Endpoint assays were conducted on study week4.At the conclusion of active monitoring, subjects were transferred to a destination protocol for long-term follow-up as per FDA guidance.onFebruary2,212stm.sciencemag.orgmpublication is presented in tables S2to S5.Of the analytes tested, 11had a threefold or more change from baseline,including four cytokines[interleukin-6(IL-6),interferon-g(IFN-g),IL-8,and IL-10], five chemokines[macrophage inflammatory protein–1a(MIP-1a), MIP-1b,monocyte chemotactic peptide–1(MCP-1),CXC chemokine ligand9(CXCL9),and CXCL10],and the soluble receptors IL-1R a and IL-2R a;IFN-g had the largest relative change from baseline (Fig.3).The peak time of cytokine elevation in UPN01and03 correlated temporally with both the previously described clinical symptoms and the peak levels of CART19cells detected in the blood for each patient.Notably,cytokine modulations were transient,and levels reverted to baseline relatively rapidly despite continued func-Table1.Patient demographics and response.CR,complete response;PR,partial response;N/A,not available.Subject UPNAge/sexkaryotypePrevious therapiesCLL tumor burden at baselineTotaldoseof CART19(cells/kg)Response day+30(duration)BM(study day)‡Blood(studyday)‡Nodes/spleen(study day)‡0165/Mnormal Fludarabine×four cycles(2002)Hypercellular70%CLL N/A 6.2×1011to1.0×1012CLL cells(day−37)1.1×109(1.6×107/kg)CR(11+months)Rituximab/fludarabine×four cycles(2005)2.4×1012CLL cells(day−14)Alemtuzumab×12weeks(2006)1.7×1012CLL cells(day−1)Rituximab(two courses,2008to2009)R-CVP×two cycles(2009)Lenalidomide(2009)PCR×two cycles(5/18/2010to6/18/2010)Bendamustine×one cycle(7/31/10to8/1/10)pre-CART190277/M del(17)(p13)*Alemtuzumab×16weeks(6/2007)Hypercellular>95%CLL2.75×1011CLL cells(day−1)1.2×1012to2.0×1012CLL cells(day−24)5.8×108(1.0×107/kg)PR(7months)Alemtuzumab×18weeks(3/2009)3.2×1012CLL cells(day−47)Bendamustine/rituximab:7/1/2010(cycle1)7/28/2010(cycle2)8/26/2010(cycle3)pre-CART190364/M del(17)(p13)†R-Fludarabine×twocycles(2002)Hypercellular40%CLLN/A 3.3×1011to5.5×1011CLL cells(day−10)1.4×107(1.46×105/kg)CR(10+months)R-Fludarabine×four cycles(10/06to1/07)8.8×1011CLL cells(day−1)R-Bendamustine×one cycle(2/09)Bendamustine×three cycles(3/09to5/09)Alemtuzumab×11weeks(12/09to3/10)Pentostatin/cyclophosphamide(9/10/10)pre-CART19*UPN02karyotype[International System for Human Cytogenetic Nomenclature(ISCN)]:45,XY,del(1)(q25),+del(1)(p13),t(2;20)(p13;q11.2),t(3;5)(p13;q35),add(9)(p22),?del(13)(q14q34),-14,del(17) (p13)[cp24].†UPN03karyotype(ISCN):46,XY,del(17)(p12)[18]/44~46,idem,der(17)t(17;21)(p11.2;q11.2)[cp4]/40~45,XY,-17[cp3].‡See the Supplementary Material for methods of tumor burden determination.o n F e b r u a r y 2 0 , 2 0 1 2 s t m . s c i e n c e m a g . o r g D o w n l o a d e d f r o mtional persistence of CART19cells.Only modest changes in cytokine levels were noted in UPN 02,possibly as a result of corticosteroid treatment.We also noted a robust induction of cytokine secretion in the supernatants from BM aspirates of UPN 03(Fig.3D and table S5).Although a pretreatment marrow sample was not available,compared to the late time point (+176),we also observed elevated levels for a number of factors in the +28marrow sample for UPN 01including IL-6,IL-8,IL-2R,and CXCL9;in contrast,compared to the pretreatment marrow sample,no elevation in cytokines was de-tected in the +31day sample for UPN 02(table S5).One of the preclinical rationales for developing CAR +T cells with 4-1BB signaling domains was a projected reduced propensity to trigger IL-2and tumor necrosis factor –a (TNF-a )secretion compared to CAR +T cells with CD28signaling domains (7);indeed,elevated amounts of soluble IL-2and TNF-a were not detected in the serum of the patients.Lower levels of these cytokines may be related to sustained clinical ac-tivity:Previous studies have shown that CAR +T cells are potentially suppressed by regulatory T cells (13),which can be elicited by either CARs that secrete substantial amounts of IL-2or by the provision of exogenous IL-2after infusion.Moreover,the TNF-a is complicit in cy-tokine storm –related effects in patients,which are absent here.Prolonged receptor expression and establishment of a population of memory CART19cells in bloodA central question in CAR-mediated cancer immunotherapy is whether optimized cell manufacturing and costimulation domains will enhance the persistence of genetically modified T cells and permit the establishment of CAR +memory T cells in patients.Previous studies have not demonstrated robust expansion,prolonged persist-ence,or functional expression of CARs on T cells after infusion (14–17).The high persistence of CART19cells that we observed at late time points for UPN 03facilitated a more detailed phenotypic analysis ofpersisting cells.Flow cytometric analysis of samples from both blood and BM 169days after infusion revealed the presence of CAR19-expressing cells in UPN 03as well as an absence of B cells (fig.S1,Aand B).These CAR +cells persisted in allthree patients beyond 4months,as shown by qPCR (Fig.2).The in vivo frequency of CAR +cells by flow cytometry closely matched the values obtained from the PCR assay for the CAR19transgene.CAR expression was also detected on the surface of 5.7and 1.7%of T cells in the blood of patient UPN 01on days 71and286after infusion (fig.S2).We next used polychromatic flow cy-tometry to perform detailed studies and further characterize the expression,phe-notype,and function of CART19cells in UPN 03using an anti-CAR idiotype anti-body (MDA-647)and the gating strategy shown in fig.S3.We observed differencesin the expression of memory and activa-tion markers in both CD4+and CD8+T cells based on CAR19expression.In the CD4+compartment,at day 56,CART19cells were characterized by auniform lack of CCR7,a predominance of CD27+/CD28+/PD-1+cells distributed within both CD57+and CD57−compart-ments,and an essential absence of CD25and CD127expression,the latter two markers defining regulatory CD4+T cells (18)(Fig.4A).In contrast,CAR −cells at this time point were heterogeneous in CCR7,CD27,and PD-1expression;expressed CD127;and also contained a substantialCD25+/CD127−population.By day 169,although CD28expression remained uni-formly positive in all CART19CD4+cells,a fraction of the CART19CD4+cells had acquired a central memory phenotype,withA CB Day (after infusion)110100100010000100000Day (after infusion)T o t a l c e l l s i n c i r c u l a t i o nDay (after infusion)110100100010000D C o p i e s /µg g D N A% W B CDay (after infusion)C o p i e s /µg gD N AWBC and CART 19: Blood CART 19: Marrow 10101010101010Fig.2.Sustained in vivo expansion and persistence in blood and marrow of CART19cells.(A to D )qPCRanalysis was performed on DNA isolated from whole blood (A to C)or bone marrow (BM)(D)samples obtained from UPN 01,UPN 02,and UPN 03to detect and quantify CAR19sequences.The frequency of CART19cells is shown as average transgene copies (A),total calculated CART19cells in circulation (B),or as a fraction of circulating white blood cells (WBCs)(C).(A)Copies CAR19/microgram DNA is calculated as de-scribed in Materials and Methods.(B)The total number of lymphocytes (total normal and CLL cells)versus total CART19+cells in circulation is plotted for all three subjects using the absolute lymphocyte count from complete blood count values and assuming a 5.0-liter volume of peripheral blood.(C)%WBC is calculated as described in Materials and Methods.(D)Bulk qPCR analysis of marrow to quantify CART19sequences.The data from patient UPN 03in (A,C,and D)has been published in (9)and is reprinted here with permission.Each data point represents the average of triplicate measurements on 100to 200ng of genomic DNA,withmaximal percent coefficient of variation (CV)less than 1.56%.Pass/fail parameters for the assay included preestablished ranges for slope and efficiency of amplification,and amplification of a reference sample.The lower limit of quantification for the assay established by the standard curve range was two copies of transgene per microgram of genomic DNA;sample values below that number are considered estimates and presented if at least two of three replicates generated a C t value with percent CV for the values 15%.CART19cells were infused at days 0,1,and 2for UPN 01and 03and at days 0,1,2,and 11for UPN 02. o n F e b r u a r y 20, 2012s t m .s c i e n c e m a g .o r g D o w n l o a d e d f r o mCCR7expression,a higher percentage of CD27−cells,the appearance of a PD-1−subset,and acquisition of CD127expression.At day 169,CAR −cells remained reasonably consistent with their day 56counterparts,with the exception of a reduction in CD27expression and a decrease in the percentage of CD25+/CD127−cells.In the CD8+compartment,at day 56,CART19CD8+cells displayed primarily an effector memory phenotype (CCR7−,CD27−,CD28−),con-sistent with prolonged and robust exposure to antigen (Fig.4B).In con-trast,CAR −CD8+T cells consisted of mixtures of effector and central memory cells,with CCR7expression in a subset of cells,and substantial numbers of cells in the CD27+/CD28−and CD27+/CD28+fractions.Al-though a large percentage of both CART19and CAR −cell populations expressed CD57,a marker associated with memory T cells with high cytolytic potential (19),this molecule was uniformly coexpressed with PD-1in the CART19cells,a possible reflection of the extensive replicative history of these cells.In contrast to the CAR −cell population,the entirety of the CART19CD8+population lacked expression of both CD25and CD127,markers associated with T cell activation and the development of functional memory cells (20).By day 169,although the phenotype of the CAR −cell population remained similar to the day 56cells,the CART19population had evolved to contain a population with features of central memory cells,notably expression of CCR7and higher levels of CD27and CD28,as well as cells that were PD-1−,CD57−,and CD127+.Effector function of CART19cells after 6months in blood In addition to a lack of long-term persistence,a limitation of previous trials with CAR +T cells has been the rapid loss of functional activity of the infused T cells in vivo.The high level of CART19cell persist-ence and surface expression of the CAR19molecule in UPN 03provided the opportunity to directly test anti-CD19–specific effector functions in cells recovered from cryopreserved PB samples.Pe-ripheral blood mononuclear cells (PBMCs)from UPN 03were cultured with target cells that either did or did not express CD19(Fig.4C and fig.S3).Robust CD19-specific effector function of CART19cells was observed by the specific degranulation of CART19cells against CD19+but not CD19−target cells,as assessed by surface CD107a expression.Notably,exposure of the CART19population to CD19+targets induced a rapid internalization of surface CAR19(see fig.S3for constitutive surface expression of CAR19in the same ef-fector cells in standard flow cytometric staining).The presence of costimulatory molecules on target cells was not required for trigger-ing CART19cell degranulation because the NALM-6line,which was used as a target in these studies,does not express CD80or CD86(21).Effector function was evident at day 56after infusion and was re-tained at day 169(Fig.4C).Robust effector function of CAR +and CAR −T cells could also be demonstrated by pharmacologic stimula-tion with phorbol 12-myristate 13-acetate (PMA)and ionomycin.ADay (after infusion)S e r u m c y t o k i n e (f o l d c h a n g e f r o m b a s e l i n e )(f o l d c h a n g e f r o m b a s e l i n e )S e r u m c y t o k i n e (f o l d c h a n g e f r o m b a s e l i n e )BCDay (after infusion)D Day (after infusion)C o n c e n t r a t i o n (p g /m l )αIL-6 IFN-γCXCL10MIP-1βMCP-1CXCL9IL-2R αIL-8 IL-10MIP-1αFig.3.Serum and BM cytokines before and afterCART19cell infusion.(A to C )Longitudinal measure-ments of changes in serum cytokines,chemokines,and receptors in UPN 01(A),UPN 02(B),and UPN 03(C)on the in-dicated day after CART19cell infusion.(D )Serial assessments of the same analytes in the BM from UPN 03.Analytes with agreater than or equal to threefold change are indicated and plotted as relative change from baseline (A to C)or as absolute values (D).In (C)and (D),a subset of the cytokine data (IFN-g ,CXCL10,CXCL9,IL-2R a ,and IL-6)from UPN 03have been pub-lished in (9)and are reprinted here with permission.Absolutevalues for each analyte at each time point were derived from a recombinant protein-based standard curve over a threefold eight-point dilution series,with upper and lower limits of quantification determined by the 80to 120%observed/expected cutoff valuesfor the standard curves.Each sample was evaluated in duplicate with average values calculated and percent CV in most cases less than 10%.To accommodate consolidated data presentation in the context of the wide range for the absolute values,data are presented as fold change over the baseline value for each analyte.In cases where baseline values were not detectable,half of the lowest standard curve value was used as the baseline value.Standard curve ranges for analytes and baseline (day 0)values (listed in parentheses sequentially for UPN 01,02,and 03),all in pg/ml:IL-1R a :35.5to 29,318(689,301,and 287);IL-6:2.7to 4572(7,10.1,and 8.7);IFN-g :11.2to 23,972(2.8,not detected,and 4.2);CXCL10:2.1to 5319(481,115,and 287);MIP-1b :3.3to 7233(99.7,371,and 174);MCP-1:4.8to 3600(403,560,and 828);CXCL9:48.2to 3700(1412,126,and 177);IL-2R a :13.4to 34,210(4319,9477,and 610);IL-8:2.4to 5278(15.3,14.5,and 14.6);IL-10:6.7to 13,874(8.5,5.4,and 0.7);MIP-1a :7.1to 13,778(57.6,57.3,and 48.1).o n F e b r u a r y 20, 2012s t m .s c i e n c e m a g .o r g D o w n l o a d e d f r o mProfound antitumor clinical activity of CART19cellsThere were no significant toxicities observed during the4days after the infusion in any patient other than transient febrile reactions. However,all patients subsequently developed significant clinical and laboratory toxicities between days7and21after the first infusion. With the exception of B cell aplasia,these toxicities were short-term and reversible.Of the three patients treated to date,there are two complete responses and one partial response lasting greater than8months after CART19infusion according to standard criteria(22).Details of past medical history and response to therapy are described in Table1. The clinical course of UPN03has been described in detail(9).In brief,patient UPN02was treated with two cycles of bendamus-tine with rituximab,resulting in stable disease;he received a third dose of bendamustine as lymphodepleting chemotherapy before CART19 cell infusion.After CART19infusion,and coincident with the onset of high fevers,he had rapid clearance of the p53-deficient CLL cells from his PB(Fig.5A)and a partial reduction of adenopathy.He de-veloped fevers to40°C,rigors,and dyspnea requiring a24-hour hos-pitalization on day11after the first infusion and on the day of his second CART19cell boost.Fevers and constitutional symptoms per-sisted,and on day15,he had transient cardiac dysfunction;all symp-toms resolved after corticosteroid therapy was initiated on day18.His BM showed persistent extensive infiltration of CLL1month after therapy despite marked PB cytoreduction.He remained asymptomatic at the time of publication.Patient UPN01developed a febrile syndrome,with rigors and transient hypotension beginning10days after infusion.The fevers persisted for about2weeks and resolved;he has had no further consti-tutional symptoms.He achieved a rapid and complete response(Fig.5, B and C).Between1and6months after infusion,no circulating CLL cells were detected in the blood by deep sequencing(Table2).His BM at1,3,and6months after CART19cell infusions showed sustainedA1.40.67.890.223.58.02939.5CCR7CD28CD127CCR7CD28CD127C0.999.187.97.10.34.65.165.726.72.60.746.551.71.265.814.34.1715.71.81236.949.49.317.644.129CD4Day 169CCR7CD28CD127CCR7CD28CD127CD45RACD27CD25CD45RACD27CD25CD45RACD27CD25CD45RACD2744.017.34.234.4CD57CD5731.932.111.424.648.218.55.128.2CD57CD57PD-1PD-1PD-1PD-150.111.01127.927.841.716.613.874.719.81.73.8CD57CD57CD57CD5735.933.610.220.352.738.94.63.936.09.814.239.974.9230.61.5CD57CD57CD57CD57CD27CD28CD27CD28CD27CD28CD27CD28CD2565.00.60.433.719.959.411.39.231.551.66.610.030.147.910.811.12.459.635.42.639.59.28.842.5CCR7CD28CD127CD57CD57CD5779.516.70.90.36.833.234.925.110.928.041.319.82542.926.16.014.244.524.516.93.7 2.025.468.875.623.70.20.56.040.339.314.316.328.831.922.937.242.318.12.414.338.222.225.36.0 4.530.359.296.6 3.414.67.41464.15.115.760.418.89.411.464.614.60.60.12.596.818.473.03.05.697.10.70.062.111.2 3.111.873.95.58.052.833.77.8 6.454.231.635.559.21.33.927.264.316.779.20.200.898.97.500.891.73.60.10.395.97.60.40.191.90.10.213.885.90.20.312.387.2C00.284.715.100.969.329.80.10.21188.60.20.56.692.74.00.21.194.73.396.6Fig.4.Prolonged surface CAR19expressionand establishment of functional memoryCART19cells in vivo.(A and B)T cell immuno-phenotyping of CD4+(A)and CD8+(B)T cellsubsets.Frozen peripheral blood(PB)samplesfrom UPN03obtained at days56and169afterT cell infusion were subjected to multipara-metric immunophenotyping for expression ofmarkers of T cell memory,activation,and ex-haustion;data are displayed after biexponentialtransformation for objective visualization ofevents.(C)Functional competence of persistingCAR cells.Frozen PB samples from UPN03ob-tained at days56and169after T cell infusion were evaluated directly ex vivo for the ability to recognize CD19-expressing target cells using CD107 degranulation assays.Presented data are for the CD8+gated population.The gating strategies for these figures are presented in fig.S2.onFebruary2,212stm.sciencemag.orgDownloadedfrom。
mimics教程第一单元什么是MimicsMimics是Materialise公司的交互式的医学影像控制系统,即为Materiaise's interactive medical image control system.它是模块化结构的软件,可以根据用户的不用需求有不同的搭配。
下面是这些模块的介绍:MIMICS软件介绍MIMICS是一套高度整合而且易用的3D图像生成及编辑处理软件,它能输入各种扫描的数据(CT、MRI),建立3D模型进行编辑,然后输出通用的CAD(计算机辅助设计)、FEA(有限元分析),RP(快速成型)格式,可以在PC机上进行大规模数据的转换处理。
MEDCAD模块:MEDCAD模块是医学影像数据与CAD之间的桥梁,通过双向交互模式进行沟通,实现扫描数据与CAD数据的相互转换。
在MIMICS的项目中建立CAD项目的方法有以下两种:1. 轮廓线建模:在分割功能状态下,MIMICS自动在分离出的掩模上生成轮廓线,MEDCAD能在给定误差的条件下自动生成一个局部轮廓线模型,进而用于医用几何学CAD模型中。
创建的CAD模型的可能方法:-B样条曲线及曲面-点,线,圆,曲面,球体,圆柱体等所有这些实体均可以iges格式输出到CAD软件中制做植入体,另一个典型的运用是用MEDCAD模块做统计分析,如测量很多不同股骨头的数据,为建立标准股骨头植入体时作参考。
2. 参数化或交互式CAD建模可在2D或3D视图中直接创建CAD对象,或者用参数设置的方式创建(如定义圆心、半径来创建一个圆),创建后可用鼠标进行交互式编辑。
方便设计验证:为验证CAD植入体的设计,MIMICS输入STL文件格式在2D视图及标准视图中显示,或在3D视图中显示,用透明方式显示解剖关系,使用这一方法可以快速实现医学影像数据在CAD设计软件中的调用。
RP-SLICE模块:Rp-slice模块在MIMICS与多数RP机器之间建立SLICE格式的接口,RP-Slice 模块能自动生成RP模型所需的支撑结构。
1-5Prototype 原形STL就是STereoLithography的缩写,它是将三维模型的表面近似表达为小三角形平面的组合Custom 风俗/习惯/自定义Prosthesis 弥补Segmentation 分割Rehearsal 排演/预演image artifacts 伪影medical staff 医务人员cranium 颅/头盖骨module 模块simulation仿真, 假装/模拟DICOM Digital Imaging and Communications in Medicine 医学数字成像和通信(标准) Visualized 直观的,直视的visualization显像,显影,,造影,想象,形象化validation,使生效,使合法/确认anatomical 解剖的,解剖学的geometry 几何形状,几何位置optical disk 频闪观测盘Slice 薄片,薄层断面,切片Prototyping systems 原型系统Patented 专利的Perforated 多孔的,穿破的Contour 轮廓,外形,Triangulated 三角的Platform ,平台Anthropometric 人体测量的Osteotomies 骨切开术Distraction 分心,精神涣散娱乐Translation 翻译,平移,转播,中继,转译Hover 翱翔, 徘徊Clipping 剪裁,限制,限幅,切断Annotations 注解Centerline 中线Voxels 三维像素Threshold 开始,开端,极限Morphology 形态学Dilate 扩大,膨胀linear X-ray attenuation coefficient 线形衰减系数tomography X线断层摄影术maxillary 上颌骨的anonymous 匿名prompt 提示wizard 向导,男巫Invert 颠倒,转换Gantry 构台,桶架Tilt 倾斜,翘起Inspection 检查Radiologist 放射线学者Alphabetical 字母的Interpolations 撺改, 添写, 插补Representation 表示法, 表现, 陈述sampling interval 进样间隔,取样间隔swapping 对换,交换binary files 二进制文件threshold value 阈值,界限值,门限值,阈限值interpolated 以内插值替换100-200Zone 地域, 地带, 地区Artifacts 假象,赝象,人为产物Cursor 光标,游标,指针,指示器Restrict 限制, 限定Polyline 多线,折线high resolution 高分辨率,高分辨contour 外形; 轮廓alter 改变identical 同一的,相同的,相等的matrix 母体, 子宫; 细胞; 脉石, 字母; 矩阵Custom 自定义,习惯, 风俗Triangulation 三角测量, 分成三角形Algorithm 算法,规则系统Downside 底侧; 下降趋势;Resolution 分辨,溶解,消退Interpolation 插入,内插,内插法,移植Femur (拉)股骨,股acquisition 采集,获得paragraph 段,节,分段,短评violate 违反,侵犯Contour 外形; 轮廓Schematic 概略的,图式的Shell 壳,外壳,去壳, 脱落;Algorithm 算法,规则系统Schematics 图表Inclusion 包埋,所括,包含Adapting 使……适应, 改编Iteration 重复, 反复, 复诵, 迭代Cycle 周期, 循环Matrix 矩阵; [计算机]矩阵Resolution 解析度, 决心, 提案,分辨率Artificial 人工的,人造的,假的Algorithm 算法,规则系统Tolerance 容差Converges 集中,会聚Buffer 缓冲(系),缓冲液,消声器,减音器,缓冲Landmark 界标,陆标, 划时代的事, 地界标Fuse ,融合,引线,导火线,保险丝performance 特征,执行,实行,操作preference 偏爱,优先,选择cross-sectional images 切面显像SCSI 小型计算机系统接口Reference 参考,参照,Directory 姓名住址录,目录Compliance 顺应性,承诺, 顺从, 屈从Propose 提出,打算,计划, 打算Dicom Digital Imaging and Communications in Medicine 医学数字成像和通信(标准)Recover 恢复, 复原, 补偿cross-section 横切面,切(断)面,横切片toggle 切换axis 轴frame 结构, 体格,帧perpendicular 垂线,垂直,正交Unload 摆脱...之负担, 倾销, 卸,,抽出,取出Tag 标签, 附属物, 名称;Reformatting 格式变换drawn. 拉, 拖曳intersect 交叉,横切,切断,横断,相交Hardware configuration 硬件配置Troubleshooting 故障排除Termination 终止, 结束daisy chain 菊花链Administrators 管理员, 管理程序Configure 配置, 装配Converter 转换器Conversion 转变Via 经由Lossy 耗损Compliant 顺从的, 适应的Cone 锥体Handle 处理,对待200-300Punche 穿孔器Islands 岛屿curling effect卷曲效应shrinkage 收缩, 缩水, 减低resin 树脂exceeding 非常的,极度的,超过, 超越tumor 瘤,肿瘤,肿胀,肿块queue 队列,排队(算)Remark 注意,言语,意见Vectors 向量, 带菌者Hatching 孵化,阴影, 影线Scheme 设计,计划,图,图解,Implemented 应用的Vector 矢量,带菌体,传病媒介Resolution 分辨,溶解,消退,分辨率,分辨能力,分解,解析,决心Program 程序,编程序,计划,规划,方案Dummy 安慰剂,对照剂,假人,人体模型Prompt 瞬发的,迅速的,提示;Spreadsheet 表格程序RP=radiophotography 放射摄影术,x线照相术Lightyear 光年stair-stepped 楼梯街compatible with 相容的,一致的bring up 养育; 提出Binary 二进位的, 二元的Queue 队列,排队(算),数据排队Resolution 分辨,溶解,消退,分辨率,分辨能力,分解,解析Flat 平的,扁的,扁平的,平坦的,伸开的Shell 壳Iteration 重复, 反复, 复诵, 迭代Aspect 外观, 方面Violation 违反, 违背, 妨碍V oxel (单一)容量成分(CT显影)Items 项目,事项Converges 集中,会聚vice versa 反之亦然drastically 激烈地, 彻底地tendon 腱entity 实体,实在,本质axes, 轴, 轴线, 轴心spline 仿样,样条anatomical 解剖的,解剖学的preparation 制备,准备,制剂,制品,标本perforated 穿孔的,穿破的VRML Virtual Reality Modelling Language虚拟现实建模语言Demo 示威, 样本唱片Interpretations 解释anatomical landmarks 解剖学标志transparent 透明的, 显然的, 明晰的Anthropometric 人体测量的Simulation 仿真,模拟Osteotomy 截骨术Referenced 参考的, 引用的第二本IGES initial graphics exchange specification 初始图形数据交换规范Linear 直线的线的,线性的,一次的Entity 实体,实在,本质Analytical 分析的, 解析的Polynomial 多项式,多项的Magnet 磁体,磁铁,磁石Caution 小心,谨慎,注意,警告Spline 仿样,样条,云形规, 齿条Orthogonal 正交的,矩形的,直角的Centerline 中线Aorta 大动脉Branches branchesCurvature 屈曲, 弯曲, 曲率Hydraulic 水力的,液压的Tortuosity 扭曲, 迂回曲折, 不当pre-processor 预处理机,前置机volumetric 容积的,体积的preprocessor 预加工器, 预处理器tetrahedron 四面体Segmentation 分割, 割断Morphology 形态学,生态学Exaggerate 夸张,夸大Protocol 草案,协议Iterate 反复,重述Split 分割,分离Shaft 轴,杆状物Intuition 直觉,Ascribed(归因,归咎)circle 外切圆inscribed circle 内切圆magnitude 大小,数量,巨大equilateral triangle 等边三角形normalize 规格化sin 正弦函数Skewness 偏斜Magnitude 大小,数量,巨大square root 平方根Inspection 检查,视察Criterion 标准,规范Diverse 不同,多样性Perpendicular 垂直,垂线Discrete 不连续的。
基于网络药理学分析冬虫夏草防治急性肾损伤的分子机制①洪涛李晓宇②李尚妹②刘华锋②③(广东医科大学附属医院肾内科,湛江 524000)中图分类号R285.5 文献标志码 A 文章编号1000-484X(2023)11-2299-06[摘要]目的:基于网络药理学分析冬虫夏草(CS)防治急性肾损伤(AKI)的分子作用机制。
方法:应用中药系统药理学数据库(TCMSP)筛选CS的有效成分和作用靶点,从DisGeNET、GeneCards、OMIM、TTD数据库筛选AKI的疾病靶点,运用Cytoscape 3.8.0软件构建“药物-成分-疾病-靶点”可视化调控网络,采用String在线数据库构建CS与AKI共同靶点的蛋白互作网络,DAVID数据库和KEGG数据库对共同靶点进行GO功能富集分析和KEGG通路富集分析,探讨其潜在分子机制。
结果:CS中筛选得到有效成分9种,防治AKI的作用靶点63个。
GO功能富集分析主要包括对药物的反应、信号转导、衰老、细胞增殖调控、细胞凋亡调控等。
CS防治AKI的主要富集通路有PI3K-Akt信号通路、MAPK信号通路、细胞凋亡通路、TNF信号通路、P53信号通路等。
结论:通过网络药理学研究方法预测了CS防治AKI的有效活性成分及作用靶点,并通过PPI网络和KEGG富集分析推测了CS通过多条信号通路调节防治AKI,涉及细胞自噬、凋亡及炎症反应等多环节生物学过程。
[关键词]冬虫夏草;急性肾损伤;网络药理学;分子机制Network pharmacology-based identification of key mechanism of Cordyceps sinensis' protection from acute kidney injuryHONG Tao, LI Xiaoyu, LI Shangmei, LIU Huafeng. Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China[Abstract]Objective:To explore potential key mechanism of Cordyceps sinensis´ (CS) protection from acute kidney injury (AKI) through network pharmacological analysis. Methods:All bioactive ingredients and target of CS were obtained from TCMSP data‐base. Targets related to AKI were obtained from DisGeNET, GeneCards, OMIM, TTD databases. Cytoscape 3.8.0 software was used to visualize "Medicine-Component-Disease-Target" networks. String online database was used to construct PPI network of common target between CS and AKI. GO functional enrichment analysis and KEGG pathway enrichment analysis were performed for common target in DAVID database and KEGG database to explore its potential molecular mechanism. Results:A total of 9 active ingredients and 63 potential targets in treatment of AKI have been identified. GO functional enrichment were mainly related to drug response, signal transduction, senescence, cell proliferation regulation, apoptosis regulation, etc. Pathways of CS to control AKI mainly enriched in PI3K-AKT signaling pathway, MAPK signaling pathway, apoptosis signaling pathway, TNF signaling pathway, P53 signaling path‐way,etc. Conclusion:Effective active ingredients and targets of CS for preventing AKI are predicted by network pharmacology. PPI network and KEGG enrichment analysis also speculates that CS regulates prevention and treatment of AKI through multiple signaling pathways, involving multiple biological processes such as autophagy, apoptosis and inflammatory response.[Key words]Cordyceps sinensis;Acute kidney injury;Network pharmacology;Molecular mechanism急性肾损伤(acute kidney injury,AKI)是多种原因造成的肾功能急性下降,是临床常见危重症。
断层扫描图像的三维重建及快速原型制造断层扫描图像的三维重建及快速原型制造引言:快速原型技术经过20多年的发展,已经发展得相当成熟。
目前CT、MRI等断层扫描技术在诊断方面应用相当广泛。
但是这些断层扫描的图片有其本身的局限性,二维图片往往让外科医生不能很好的对病理进行分析。
翻阅大量的序列断层图片,不及将这些图片三维重建,将实体模型拿在手上进行分析得到的信息多。
比利时Materialise公司开发的Mimics是连接断层扫描图片与快速原型制造的桥梁。
图片的导入针对目前标准的DICOM文件格式,Mimics提供了自动的导入功能。
用户只需要在导入向导的指引下就可以导入整个目录下的文件或是部分文件。
同时,还可以通过半自动的方式导入BMP和TIFF文件,手动的方式导入其他的文件。
组织的提取及三维重建导入原始的断层图片后,MIMICS会自动计算生成冠状面图和矢状面图。
Mimics 用三个视图来显示这三个位置的图片,并且这三个视图是相会关联的,可以通过鼠标和定位工具栏快速定位,如图1所示。
右上角的图是原始的扫描图像,左上角和下角是由原始横断面图像计算生成的冠状面和矢状面图像。
红线指示横断面图像的位置,黄线指示冠状面图像的位置,绿线指示矢状面位置。
图1 Mimics的用户界面断层图片中,不同组织的灰度值不同,故此可以通过阈值来提取相应的组织,如图2所示。
图 2 设置恰当的阈值提取组织从图中可以看出,着色的象素其灰度值落在阈值之间,故其被提取。
准确的设置阈值是提取组织的关键,阈值提取组织的时候,可以通过看图,检查提取的组织是否合适。
图3-A的阈值左区间设置得太低,故而提取了许多噪点。
图3-B的阈值左区间设置得太高,故而有许多骨组织丢失。
图3A 左侧阈值设置太低图3B左阈值设置过高Mimics会将提取的象素存放在一个蒙罩(Mask)里,同时Mimics提供一系列的工具编辑修改蒙罩,从而提取所需的组织。
编辑好的蒙罩可以用来生成3D模型,这样就实现了2D断层扫描图片到三维实体的转换,如图4所示。
医学文献检索复习资料第一章一、信息、知识、情报、文献(选择、判断改错)1、信息:是物质存在或运动方式与状态的表现形式或反映,是现实世界事物的反映,它提供了客观世界事物的消息、知识,是事物的一种普遍属性。
2、知识:是人类在认识和改造客观世界实践中获得的对事物本质的认识和经验的综合,是人们通过实践对客观事物及其运动过程和规律的认识。
3、情报:是指人们以各种方式传递与交流的具有一定目的与时效的信息,是人们为一定目的搜集的有使用价值的知识或信息。
情报的重要属性:知识性、传递性、效用性。
4、文献:是指以文字、图象、公式、声频、视频、代码等手段记录或描述在一定的物质载体上,并能起到存储和传播信息情报和知识作用的一切载体。
(记录有知识的一切载体。
)文献由三个基本要素构成:内容上的知识或信息;揭示和表达知识信息的表示符号;记录信息符号的物质载体。
信息、知识、文献、情报的包含关系:信息、知识、情报必须固定在一定的物质载体上,形成文献后才能进行传递,才能被人们所利用,文献是信息、知识、情报存储、传递、利用的重要方式。
信息可以成为情报;信息是知识的重要组成部分,但不是全部;情报是知识或信息经传递并起作用的部分。
第二章医学文献信息资源一、文献信息资源类型的划分1、按载体类型划分:(1)书写型文献:古代文献、书法作品、手稿、书信、原始记录等(2)印刷型文献:图书、期刊、会议文献、政府出版物、专利文献、技术标准、产品资料、学位论文、技术档案(3)缩微型文献:微缩胶卷、微缩胶片、微缩照片等(4)视听型文献:唱片、录音带、录像带、科技电影、幻灯片、电视片等(5)电子型文献:电子型文献按发布形式分为:①参考数据库:A.书目数据库:中药在线、CBM、PubMedB.文摘和索引数据库②全文数据库③事实数据库④搜索引擎/分类指南⑤网络学术资源学科导航⑥FTP资源⑦其他2、按出版类型划分:(1)图书:是现代出版物中最普通的一种类型,有封面、书名、作者、出版地、出版者,并装订成册。
-专家述评-重视白内障防治药物研发,降低白内障患者致盲率王延东中山大学中山眼科中心药学部,广州510060通信作者:王延东,Email:wangyandong@【摘要】随着我国人口老龄化社会的到来以及人们生活方式的改变,年龄相关性眼病、代谢相关性眼病、高度近视引发的眼底病变凸显,成为我国当前主要的致盲眼病0目前,手术治疗仍是白内障唯一的治疗手段,但白内障手术是有创治疗方法0我国老龄化人口的快速增加对年龄相关性白内障的预防以及延缓早中期白内障的进展速度也提出了挑战'白内障的发病机制包括晶状体蛋白质变性、氧化应激及晶状体上皮细胞凋亡,这些发病机制为白内障治疗药物研发提供了治疗靶点-虽然迄今为止尚无经过证实有效的白内障治疗药物,但在眼科工作者与药学研究者的共同努力下,我国的白内障药物研究仍取得了巨大进步-研发白内障治疗药物对于白内障患者选择无创治疗方式、避免手术的创伤及并发症、扩大白内障早期治疗的机会以及降低医疗成本有重要意义-我们应该在现有成绩的基础上面对挑战,继续努力,重视白内障防治药物的研发,从而进一步降低白内障的致盲率-【关键词】白内障/治疗;药物研发;致盲率基金项目:广东省自然科学基金项目(2016A030313294)DOI:10.3760/cma.?cn115989-20201102-00726Promoting the research and development of drug for cataract and reducing the blindness rate of cataractWang YandongZhongshan Ophthalmic Center,Sun Yat-sen University,Guangzhou510060,ChinaCorresponding aut—os:Wang Yandoog,Emaii:Abstract With the aging of the population and changes of peepleJ lifestyle,age-related eye diseese,metabolic-related eye diseese and fundus lesione ccused b-high myopia become the main ccusee of blindnese inChina.Up te now,the only therapy for age-related cctaraet is still surgery to remove and replace the opacified lens.However,surgery for cctaract is an invesive therapy,and the rapid increese of aging population and rising incidence ofcctaract put forward a huge challenge foe the prevention of cctaract and retarding the progress of cctaract.Cataractpathogenesis includes protein cwstalyzation partiaHy unfolding and subsequently aagravating,oxidative stress and lensepitheliat cells apoptosis,and these provide treatable targets foe cctaract drugs.Based on these pathogenesis,scientistshave been looking for possible treatment drugs.Although se faa there is no proven effective drugs,ophthalmolovists andpharmacists have made an exciting progress and novee discovea in China.Pursuing a pharmacolovic treatrnent foecataract is of important significance for selecting non-invasive therapies based on patients wiH,aveiding surgicctcomplicotions,expanding access to cataract treatrnent and reducing healthcare costs.We should keep making effort oneeeeaech and deeeeopmenCoodeugooecaaeacC,in oedeeooueCheeeeduceChebeindneeeeaeoocaaeac.Key words Cataracts/therapy;Drug discover;Blindness rateFund program:Guangdong Naturat Sciencc Foundation(2016A030313294)DOI:10.3760/cma.?cn115989-20201102-00726随着我国经济的增长以及医疗水平的提升,我国人口老龄化时代的快速到来以及对各种疾病认识和研白内障的手术率已经得到明显提高-然而,随着我国究的深入,各种类型的白内障患病人数不断上升,尤其是年龄相关性白内障患者,同时医疗资源仍存在配置不均匀的问题。
mimics和inhibitor原理-回复mimics和inhibitors是生物学和医学领域中常见的概念。
它们在研究和开发新药物、治疗疾病和了解生物过程等方面起着重要的作用。
本文将详细介绍mimics和inhibitors的原理,展示它们在科学研究中的应用。
通过一步一步的解释,我们可以更好地理解这些概念。
首先,让我们从mimics(模拟物)开始。
在生物学中,mimics是指具有与某种生物分子或生物过程相似的特征或功能的物质。
这些物质可以是化合物、分子、药物或其他类型的生物分子。
通过模拟目标分子或过程,mimics能够模仿其作用方式并与其相互作用。
那么,为什么要使用mimics呢?有几个原因。
首先,mimics可以用于研究生物分子的作用机制。
通过设计和合成具有与目标分子相似特征的mimics,研究人员可以深入了解目标分子如何与其他分子相互作用以及其所起的生物作用。
其次,mimics还可以用于开发新药物。
通过了解目标分子的作用机制,研究人员可以设计和合成具有类似作用的mimics,用作潜在的药物分子。
这种策略有助于发现新的治疗方法和更有效的药物。
接下来,让我们转向inhibitors(抑制剂)。
与mimics相反,inhibitors 是指能够减弱或阻止某种生物分子或生物过程的活性或作用的物质。
在生物学和医学研究中,抑制剂被广泛用于研究和治疗各种疾病。
抑制剂的工作原理有多种方式。
首先,抑制剂可以与目标分子结合,阻止其与其他分子的相互作用。
这种结合可以是可逆的或不可逆的,具体取决于具体的分子和研究目的。
其次,抑制剂还可以影响目标分子的活性。
它们可以阻断目标分子的活性中心或与其结合的底物结合点,从而干扰其正常的生物作用。
抑制剂在药物开发和治疗中发挥着重要的作用。
例如,一些疾病的发展与某些酶的过度活化有关。
通过设计和合成特定的酶抑制剂,研究人员可以干扰过程并阻止疾病的进展。
此外,抑制剂也可以用于研究生物过程的调节机制。
A Collection of Target Mimics for Comprehensive Analysis of MicroRNA Function in Arabidopsis thaliana Marco Todesco1.,Ignacio Rubio-Somoza1.,Javier Paz-Ares2,Detlef Weigel1*1Department of Molecular Biology,Max Planck Institute for Developmental Biology,Tu¨bingen,Germany,2Department of Plant Molecular Genetics,Centro Nacional de Biotecnologı´a–Consejo Superior de Investigaciones Cientı´ficas,Madrid,SpainAbstractMany targets of plant microRNAs(miRNAs)are thought to play important roles in plant physiology and development.However,because plant miRNAs are typically encoded by medium-size gene families,it has often been difficult to assess their precise function.We report the generation of a large-scale collection of knockdowns for Arabidopsis thaliana miRNA families;this has been achieved using artificial miRNA target mimics,a recently developed technique fashioned on an endogenous mechanism of miRNA regulation.Morphological defects in the aerial part were observed for,20%of analyzed families,all of which are deeply conserved in land plants.In addition,we find that non-cleavable mimic sites can confer translational regulation in cis.Phenotypes of plants expressing target mimics directed against miRNAs involved in development were in several cases consistent with previous reports on plants expressing miRNA–resistant forms of individual target genes,indicating that a limited number of targets mediates most effects of these miRNAs.That less conserved miRNAs rarely had obvious effects on plant morphology suggests that most of them do not affect fundamental aspects of development.In addition to insight into modes of miRNA action,this study provides an important resource for the study of miRNA function in plants.Citation:Todesco M,Rubio-Somoza I,Paz-Ares J,Weigel D(2010)A Collection of Target Mimics for Comprehensive Analysis of MicroRNA Function in Arabidopsis thaliana.PLoS Genet6(7):e1001031.doi:10.1371/journal.pgen.1001031Editor:Gregory P.Copenhaver,The University of North Carolina at Chapel Hill,United States of AmericaReceived March17,2009;Accepted June17,2010;Published July22,2010Copyright:ß2010Todesco et al.This is an open-access article distributed under the terms of the Creative Commons Attribution License,which permits unrestricted use,distribution,and reproduction in any medium,provided the original author and source are credited.Funding:Supported by an EMBO Long-term Fellowship(IR-S),Marie Curie RTN SY-STEM,grant BIO2008-04715from Spanish Ministry of Science and Innovation (MICINN)(JP-A),French-German-Spanish Trilateral program on Plant Genomics(TRANSNET project funded by MCINN and BMBF;JP-A and DW),European Community FP6IP SIROCCO(contract LSHG-CT-2006-037900),a Gottfried Wilhelm Leibniz Award of the DFG,and the Max Planck Society(DW).The funders had no role in study design,data collection and analysis,decision to publish,or preparation of the manuscript.Competing Interests:The authors have declared that no competing interests exist.*E-mail:weigel@.These authors contributed equally to this work.IntroductionMicroRNAs(miRNAs)are a class of small RNA(sRNA) molecules that has recently emerged as a key regulator of gene activity.In plants,miRNAs are released from larger precursors (pri-miRNAs)in the nucleus mainly,by DICER-LIKE1(DCL1) [1].The resulting sRNA duplex is methylated and translocated to the cytoplasm where it can be loaded into an RNA-induced silencing complex(RISC)that includes a member of the ARGONAUTE(AGO)family as catalytic component.The RISC can then recognize mRNAs containing sequences complementary to the loaded miRNA[2].In plants,cleavage of the target mRNA is an important mechanism for plant miRNA action,but there are also direct effects on protein accumulation,as reported for many animal miRNAs[3–11].The spatio-temporal expression pattern of miRNA genes is regulated to a large extent at the transcriptional level,and different members of a miRNA family can have distinct,specialized expression domains[12–17].An additional layer of regulation in miRNA action has been reported by Franco-Zorrilla and colleagues[18].IPS1(INDUCED BY PHOSPHATE STARVATION 1)encodes a non-coding RNA with a short motif that is highly complementary to the sequence of miR399,which like IPS1is involved in the response to phosphate starvation[19–23].In contrast to regular miRNA target sites,the IPS1sequence contains a three-nucleotide insertion in the center,corresponding to the position where normally miRNA-guided cleavage takes place,and this bulge in the miRNA/target pair prevents endonucleolytic cleavage of IPS1transcripts.This results in sequestration of RISC miR399,leading to a reduction of miR399activity.A similar phenomenon,negative regulation of small RNA activity by a partially complementary mRNA,has been recently described in bacteria as well[24,25].MiRNA target mimicry can be exploited to study the effects of reducing the function of entire miRNA families[18].Simulta-neous inactivation of all miRNA family members by constructing multiply mutant lines has so far been achieved for only two relatively small families[16,26].Plant target mimics are conceptually similar to miRNA sponges,used to reduce miRNA activity in animals.MiRNA sponges are transcripts containing multiple miRNA binding sites that compete with endogenous target mRNAs,thereby reducing the efficiency of the correspond-ing miRNA[27].Although in animals perfect-match miRNA binding sites seems sufficient to sequester miRNAs[28],such optimal sites would be generally cleaved in plants,and they would not succeed in sequestering the miRNA-loaded RISC.Consistent with this,plants overexpressing non-modified versions of miR156 and miR319target genes show much milder phenotypes than plants expressing the corresponding target mimics[18,29,30]. Modifications of the miRNA binding site that prevent cleavage butstill allow miRNA binding are therefore required to reduce miRNA activity in plants.Here,we present a collection of transgenic plants expressing artificial target mimics designed to knockdown the majority of Arabidopsis thaliana miRNA families.One fifth of these lines have obvious morphological defects,which is in the same range as the approximately10%of miRNA knockouts that caused phenotypic abnormalities or lethality in Caenorhabditis elegans[31].We found a clear correlation between the evolutionary conservation of plant miRNA families and their effect on aerial plant morphology. Results/DiscussionDesign of target mimicsWe generated artificial target mimics for73different families or subfamilies of miRNAs and expressed them in Arabidopsis thaliana plants under the control of the constitutive35S CaMV promoter. As described[18],we modified the23nucleotide,miR399-complementary motif in IPS1.The different constructs,and the corresponding transgenic lines,are named‘‘MIM’’,followed by the numeric identifier of the targeted miRNA family or subfamily. We targeted all miRNA families reported in miRBase(http:// /sequences/index.shtml)and ASRP ()[32]at the beginning of2007, plus some of the miRNAs described subsequently[33].The majority of the analyzed families have only been described in Arabidopsis thaliana and Arabidopsis lyrata[34,35].The remaining families are shared with other angiosperms,and less than a quarter has been detected in non-flowering plants,including gymno-sperms,ferns or mosses[32,33,36,37].A complete list of MIM constructs,and the primer pairs used to generate them,can be found in Table S1.For miRNA target predictions,see[8,33], unless stated otherwise.A single artificial target mimic could be designed for most miRNA families.The mature miRNAs produced by members of the miR169and miR171families differ slightly,and different target mimics were designed for these subfamilies.Two target mimics were also designed for the miR161family,which produce two mature miRNAs that have only partially overlapping sequences,and that target similar subsets of the PPR gene family [38].Conversely,some miRNA families have very similar sequences and overlapping in vivo targets(e.g.,miR159/319, miR156/157and miR170/171a),and artificial target mimics might not be able to unambiguously discriminate between different miRNAs.In some cases,the sequence of the bulge in the miRNA/target mimic pair had to be modified.For example,maintaining the original central sequence of IPS1in MIM172could have reconstituted a cleavage site for miR172.Consistent with such modifications being important,plants expressing the appropriately modified version of MIM172showed an altered phenotype(see below),whereas plants expressing an initial version of MIM172in which a putative miR172cleavage site was present(MIM172cs)did not.Moreover,plants expressing a MIM172version with only a single-nucleotide mismatch corresponding to position11of the mature miRNA(MIM172sn)did not show any abnormal phenotype either,suggesting that the three-nucleotide bulge is required for target mimic activity(Figure1).Effects of target mimics on morphology and developmentWe generated at least20independent transformants for each of 75separate constructs.Of these,15,targeting14different families, caused reproducible phenotypes in the shoot system of the plants, which are described below.Phenotypic alterations were consistent across most,if not all,independent transformants examined for each construct.An example of the phenotypic variation among primary transformants is shown in the histograms in Figure1.An overview of all lines with morphological defects is given in Table1, together with the main target genes of the corresponding miRNA family and a list of other taxa in which they can be found.The phenotypes of MIM156and MIM319plants have been briefly described before[18,39].All miRNA families whose inactivation resulted in visible phenotypical alterations are conserved among the angiosperms,and most of them are also found in non-flowering plants.MIM156and MIM157plants(Figure2)had reduced leaf initiation rates,such that they flowered at about the same time as wild type,but with only two or three true leaves.This phenotype is similar to what is seen in plants carrying non-targetable versions of SPL9or SPL10,two of the miR156/157targets,and opposite of plants overexpressing miR156b or spl9spl15double mutants [10,40–42].In addition,these plants had bent,spoon-shaped cotyledons.The few rosette leaves were characterized by serrated margins,indicating adult leaf identity,consistent with a role of miR156and its targets in controlling phase change[30].MIM159plants had extensive pleiotropic defects,and similar phenotypes were observed in most MIM319lines.These plants had reduced stature,with rounder,upward curled leaves(Figure2), shorter stem internodes,and smaller flowers with short sepals, reduced petals and anthers that did not develop completely.More severe MIM319lines were progressively smaller,had warped leaves and lacked well-developed petals(Figure3A).Stem elongation was often completely suppressed(Figure3B).Most plants had reduced fertility,and this phenotype was particularly severe in MIM319plants,for which only a few viable seeds could be recovered after they were grown for prolonged periods at16u C in long days.Both vegetative and floral phenotypes reminiscent of MIM159defects have been reported for plants that express non-targetable forms of miR159target genes[29],and in plants doublyAuthor SummaryMiRNAs are small RNA molecules that play an important role in regulating gene function,both in animals and in plants.In plants,miRNA target mimicry is an endogenous mechanism used to negatively regulate the activity of a specific miRNA family,through the production of a false target transcript that cannot be cleaved.This mechanism can be engineered to target different miRNA families. Using this technique,we have generated artificial target mimics predicted to reduce the activity of most of the miRNA families in Arabidopsis thaliana and have observed their effects on plant development.We found that deeply conserved miRNAs tend to have a strong impact on plant growth,while more recently evolved ones had generally less obvious effects,suggesting either that they primarily affect processes other than development,or else that they have more subtle or conditional functions or are even dispensable.In several cases,the effects on plant development that we observed closely resembled those seen in plants expressing miRNA–resistant versions of the major predicted targets,indicating that a limited number of targets mediates most effects of these miRNAs.Analyses of mimic expressing plants also support that plant miRNAs affect both transcript stability and protein accumulation. The artificial target mimic collection will be a useful resource to further investigate the function of individual miRNA families.mutant for miR159a and miR159b [26].In particular,upward curled leaves have been observed in plant expressing non-targetable forms of MYB33,which can be targeted both by miR159and miR319[43].Milder MIM319lines showed different leaf defects,with leaves curled downward (Figure 2).This is consistent with what has been reported for plants that express non-targetable forms of TCP2and TCP4,which are both exclusive miR319targets [29],suggesting that target mimics can at least partially discriminate between these two miRNA families.Serrated and hyponastic leaves were seen in MIM160plants (Figure 2),in agreement with the phenotype of plants that express non-targetable versions of ARF10or ARF17,two of the three miR160targets [44,45].In addition,MIM160plants were smaller than wild pared to other constructs,fewer transformants were recovered,consistent with the known requirement of miR160for seed viability or germination [44].A different type of leaf serration was caused by MIM164(Figure 2),similar to what has been reported for plants expressing a non-targetable version of CUC2,one of the miR164targets,and for plants lacking one of the miR164isoforms,miR164a [13].While expression of MIM160affected the entire leaf,with the serrations being regular and jagged,MIM164caused mainly serration of the basal part of the leaf,with more irregular androunded sinuses and teeth (Figure 3C).Although carpel fusion defects have been described for plants lacking miR164c [12],the carpel defects in MIM164plants seemed to be different,with ectopic growths forming at the valve margins (Figure 3D),resembling those seen in the cuc2-1D mutant,in which a point mutation affects the miR164complementary motif in CUC2[46].In some cases,this tissue could develop into adventitious pistil-like structures (Figure 3E).Rounder leaves with an irregular surface,which appeared to be hollowed out between the main veins,were caused by MIM165/166.Younger leaves tended also to be cup-shaped (Figure 2).Targets of miR165/166,including the transcription factor-encoding genes PHAVOLUTA and PHABULOSA ,control leaf polarity,and dominant mutations that disrupt the miRNA target site in these genes cause severe alterations in leaf morphology [47–49].A substantial delay in flowering was observed in MIM167plants,which flowered with 20.864.2(mean 6standard deviation;n =30)leaves in long days,compared to 13.060.9rosette leaves in wild-type plants (Figure S1A and Figure S2).These plants had in addition twisted leaves (Figure 2),as well as defects in the maturation of anthers (Figure 3F)and in the development and shattering of seeds,which oftenremainedFigure 1.Requirement of a bulge at the cleavage site for target mimicry.(A)A target mimic with an unmodified central sequence (MIM172cs ),which retained complementarity to the central portion of miR172across the cleavage site (red line)opposite position 10to 11of the miRNA,did not change flowering time.Modification of the central sequence (TCTA to GAGT;MIM172)restored a three nucleotide bulge found in IPS1and generated a functional target mimic,causing a delay in flowering.However,a single nucleotide mismatch introduced into the center of an authentic miR172target site (MIM172sn ),but without a bulge,was not sufficient to reduce miR172activity.(B)Four-week old plants grown at 23u C in long days.MIM172cs and MIM172sn are phenotypically indistinguishable from wild-type Col-0plants (see also Figure S1B).(C)Distribution of flowering times of primary transformants grown in the same conditions;compare with Col-0plants transformed with an empty binary vector in Figure S2.doi:10.1371/journal.pgen.1001031.g001attached to the dehiscent siliques(Figure3G),resulting in reduced seed production and germination(not shown).This is consistent with what has been observed in plants that express a non-targetable form of the miR167target ARF6or ARF8.Such plants have smaller leaves and are often sterile due to defects both in ovule and anther development[17].Effects on flowering time have not been previously associated with miR167[17,50],and the late-flowering phenotype of MIM167plants reveals a new role for this miRNA family.Two constructs were used to downregulate different subfamilies of miR169family,whose main targets are HAP transcription factors.MIM169was designed for miR169a,b,c,h,i,j,k,l,m and n,and MIM169defg for miR169d,e,f and g.Both target mimics reduced the size of transgenic plants(Figure2).MiR170and miR171target a group of SCARECROW-like transcription factor genes[9],and both MIM170and MIM171A plants had round,pale leaves(Figure2),as well as defective flowers, with sepals that did not separate properly,resulting in reduced fertility (Figure3H and3I).Expression of target mimics against the b and c members of the miR171family did not confer any phenotype, suggesting less important roles for these two miRNAs.MIM172plants were also late flowering,with20.063.5(n=30) rosette leaves in long days(Figure S1B),consistent with the flowering time phenotype of plants that have increased expression of miR172targets[4,6,51].In addition,leaves of MIM172plants appeared to be somewhat narrower than those of wild type,and mildly curled downward,and severe MIM172lines presented reduced apical dominance(not shown).In contrast to plants that express a non-targetable version of AP2[52],flowers of MIM172 plants were normal.These differential effects could be due to the particularly high levels of miR172levels during early flower development[6].MiR393targets a small group of auxin receptor genes.MIM393 plants had mild defects in leaf morphology,with narrow leaves that were curled downward(Figure2).Leaf epinasty is often associated with high auxin levels[53],and is consistent with an increase of auxin signaling caused by downregulation of miR393 activity.Finally,epinastic leaves were observed also in MIM394plants (Figure2).MiR394is predicted to target a gene encoding an F-box protein.Effects of target mimics on miRNA target genes Artificial target mimics are thought to sequester their target miRNAs,presumably by stably binding to miRNA-loaded RISCs. To obtain additional evidence for such interactions,we embedded a functional MIM159site in the39-UTR of a triple-Enhanced Yellow Fluorescent Protein(EYFP)reporter;stable recruitment of RISC miR399to the mimic site could be expected to interfere with EYFP translation.In80%of MIM159expressing T1plants,as in control plants,the EYFP transgene was completely silenced.In the remaining20%,we detected EYFP signal that was strongly reduced in the region where MIR159genes are known to be expressed(Figure4A)[26].In addition,these plants presented the typical phenotypic defects of MIM159plants,confirming that the EYFP:MIM159construct functions properly as a target mimic.Table1.Artificial target mimics causing visible phenotypes.Mimic miRNAs*Phenotype miRNA targets Conservation**MIM156miR156Longer plastochron.Altered morphology ofcotyledons and true leaves.SPL2,SPL3,SPL4,SPL5,SPL6,SPL9,SPL10,SPL11,SPL13,SPL151,2,3,4MIM157miR157Similar to MIM156.SPL2,SPL4,SPL5,SPL6,SPL9,SPL10,SPL11,SPL13,SPL15MIM159miR159Reduced size and stature.Thicker,upward curled leaves.Incomplete development of sepals,petals and anthers.MYB33,MYB65,MYB81,MYB97,MYB101,MYB104,MYB120,DUO11,2,3MIM160miR160Smaller plants,with serrated and curled upward leaves.ARF10,ARF16,ARF171,3,4MIM164miR164Partially serrated leaves.Ectopic tissue growth in thedeveloping fruit.NAC1,CUC1,CUC2,ANAC079,ANAC092,ANAC100,AT3G129771MIM165/166miR165/miR166Rounder leaves.Younger leaves cup-shaped,with an irregular surface.PHV,PHB,REV,ATHB-8,ATHB-151,2,3MIM167miR167Delayed flowering.Twisted leaves,rolleddownward.Defects in anther and seed development.ARF6,ARF81,3MIM169miR169a–c,h–n Reduced rosette size.HAP2A,HAP2B,HAP2C,AT1G17590,AT1G54160,AT3G20910,AT5G065101MIM169defg miR169dd–g Similar to MIM169.HAP2A,HAP2B,HAP2C,AT1G17590,AT1G54160,AT3G20910,AT5G06510MIM170miR170Round leaves of pale green color.Anthesisdefects,causing reduced fertility.AT2G45160,AT3G60630,AT4G00150MIM171a miR171a Similar to MIM170.AT2G45160,AT3G60630,AT4G001501,2,3,4 MIM172miR172Delay in flowering time.Narrow leaves,mildly rolleddownward.Reduced apical dominance.AP2,TOE1,TOE2,TOE3,SMZ,SNZ1MIM319miR319Similar to MIM159.In some lines,leavescurled downward.TCP2,TCP3,TCP4,TCP10TCP24,MYB33,MYB65,MYB81,MYB97,MYB104,MYB1201,2,3,4MIM393miR393Narrow leaves,curled downward.AFB2,AFB3,TIR1,GRH1,AT3G236901 MIM394miR394Narrow leaves,curled downward.AT1G273401 *If no letter is given,the entire family was targeted.**The conservation of miRNA families in the following groups is reported:(1)Other dicots and monocots,(2)gymnosperms,(3)ferns,(4)mosses. doi:10.1371/journal.pgen.1001031.t001RISC miRNA sequestration in turn should relieve target genes from miRNA-dependent regulation,resulting in increased levels of the encoded protein.In agreement with such a scenario,activity levels of a genomic MYB33:GUS reporter were markedly increased in MIM159plants (Figure 4A).In analogy with EYFP:MIM159,reporter activity was increased in the tissues expressing MIR159genes [26],as expected.Sequestration of RISC miR399by the natural target mimic IPS1prevents miR399-guided cleavage of PHO2mRNA,thus increas-ing PHO2mRNA levels [18].To assess the effects of artificial target mimics on the levels of mRNA of miRNA target genes,we tested them by reverse transcription followed by quantitative PCR (qRT-PCR)in a subset of MIM lines.We preferentially analyzed organs in which miRNA abundance was high according to the ASRP database [32,54],or organs with major phenotypic alterations in MIM lines.Two independent lines were tested foreach construct.Among the miRNA targets,we chose ones known to induce phenotypic defects when expressed as non-targetable forms [44,45,47]and ones that show altered expression in miRNA biogenesis mutants [32,54,55].PCR products spanned the miRNA target sequence,allowing quantification of the attenuation in slicing activity by the corresponding miRNA.Surprisingly,in most cases there were no major changes in target transcript levels (Figure 4B and Figure S3).For comparison,we examined the expression of the same miRNA target genes in seedlings of several mutants impaired in small RNA biogenesis and function,including dcl1-100,se-1,hyl1-2and ago1-27,and in plants overexpressing viral silencing suppressors that are known to counteract the action of the small RNA machinery,including P1/HC-Pro,P0,P19and p21[56–60].In most cases,the changes seen in MIM lines correlated with those seen in miRNA biogenesis mutants.StrongereffectsFigure 2.Leaf rosettes of target mimic expressing plants.Three-week-old plants.Bar corresponds to 1cm for all panels.doi:10.1371/journal.pgen.1001031.g002were observed only in dcl1-100plants (Figure 4C).These results are consistent with what has been observed in microarray studies of miRNA biogenesis mutants,including other dcl1alleles,se and hyl1[55,61].As in animals,inhibition of translation is an important component of miRNA function in plants [4,6,11].To test whether artificial mimics impact miRNA effects independent of changes in target transcript accumulation,we monitored the protein levels produced by CIP4,a gene that is regulated by miR834through translational inhibition [5,62].In MIM834lines,CIP4levels wereappreciably increased,while CIP4mRNA levels were unchanged (Figure 4D).Direct effects on protein translation could explain the absence of a clear correlation between target mRNA levels and plant phenotype in plants expressing artificial target mimics.Finally,we investigated the levels of mature miRNAs in plants expressing artificial target mimics.In all MIM lines we examined,levels of the targeted miRNA were decreased,suggesting that unproductive interaction of RISC miRNA with a decoy affects miRNA stability (Figure 4E).Although such an effect has not been observed in case of the endogenous IPS1-miR399interaction[18],Figure 3.Details of defects observed in target mimic expressing plants.(A)Smaller flowers in severe MIM319lines.The most strongly affected flowers lacked petals and did not have fully developed anthers (left side);in milder lines,flowers had short sepals,narrow petals,but were fertile (middle).Two flowers from wild type Col-0are shown on the right side of the panel.(B)Severe MIM159and MIM319lines were very small and compact,without any stem elongation.(C)Leaves of MIM164plants (compared to a leaf from wild type Col-0,on the far left).(D,E)Developing fruits of MIM164with ectopic growths emanating from valve margins (D),which can develop into pseudo-pistils in severe lines (E).(F)Anthers in MIM167lines did not mature completely (top),resulting in reduced pollen production (compared to a wild type Col-0flower,bottom).(G)Seeds of MIM167plants often do not fill completely,and remained attached to the dried silique (compared to a silique of wild type Col-0,on the right).(H,I)MIM171A lines suffered from defects in the separation of sepals,which prevented emergence of the pistil (H),and caused the plants to be mostly sterile (I,on the left,compared to a wild-type Col-0plant,on the right).Bars correspond to 1cm in (A–C)and I,and to 0.1cm in (D–H).doi:10.1371/journal.pgen.1001031.g003a similar reduction in small RNA levels triggered by a target mimic has been reported in bacteria [24,25].ConclusionsWe have generated a collection of transgenic plants expressing artificial target mimics designed to reduce activity for most of the known miRNA families in Arabidopsis thaliana .Inhibiting the function of 14out of 71miRNA families with target mimics led to morphological abnormalities.All of these families belong to the more abundant and widely conserved miRNA families,which were the first ones to be discovered (Table 1).This agrees with results from experiments in which miRNAs were overexpressed,miRNA target genes were mutated,or miRNA genes were inactivated by conventional knockouts [reviewed in 63].Together,these findings are consistent with the scenario of frequent birth and death of miRNA genes,with only a few becoming fixed early onduring evolution because they acquired a relevant function in plant development [33,36].More recently evolved,species-specific miRNAs could instead play a role in adaptation to certain abiotic or biotic challenges,or have no discernable function at all.Some miRNAs are known to regulate physiological traits,and they do not cause morphological abnormalities under standard benign conditions [20,21,64].Such conditional effects would have escaped our screen,as would have defects in the root system of the plant.Moreover,compared to expression of non-targetable forms of miRNA target genes,or miRNA loss-of-function mutants,the defects of MIM plants were often weaker.Examples are the absence of an altered floral phenotype in MIM172plants,which is seen in plants that express a non-targetable version of AP2under the control of normal regulatory sequences [52],or the extra-petals phenotype seen in mir164c mutants,but not in MIM164plants [12].Another caveat is that some miRNAs mightbeFigure 4.Effects of artificial mimics on levels of miRNAs and miRNA targets.(A)Nine-day-old plants.Introduction of a MIM159fragment into the 39UTR silences a constitutively expressed 3xEYFP in the MIR159expression domain (compare p35S:3xEYFP and p35S:3xEYFP-MIM159),which is revealed in the pMIR159:GUS lines.MiR159activity is also indirectly revealed by comparing the effect of expressing MIM159in a genomic MYB33:GUS line.(B)Transcript levels of select miRNA targets in two independent lines for each MIM construct (represented by bars of different shades of gray).(C)Expression levels of miRNA targets in mutants impaired in miRNA biogenesis or targeting.Expression values are reported as the average of two biological and two technical replicates,and are normalized to the expression levels in wild type Col-0plants (dotted line).(D)CIP4mRNA and protein levels in four independent MIM834lines.Band intensity relative to the wild-type control is reported.(E)Levels of mature miRNAs in several MIM lines.U6accumulation is shown as control.Increased accumulation of miR156(lower band in the blot)was observed upon expression of a resistant version of a miR156target (consistent with what observed for miRNA156a precursor levels in [39])or inhibition of miRNA activity in the ago1-27mutants.The decrease in miR156levels in MIM156plants is then not an indirect consequence of increased SPL transcript levels.doi:10.1371/journal.pgen.1001031.g004。